A Phenotypic Approach to the Discovery of Compounds that Promote Non-Amyloidogenic Processing of the Amyloid Precursor Protein: Toward a New Profile of Indirect β -Secretase Inhibitors

Marion Gay,^{a\$} Caroline Evrard,^{a\$} Florian Descamps,^{a\$} Pascal Carato,^{a#} Nicolas Renault,^b Mathilde Coevoet,^a Sabiha Eddarkaoui,^a Catherine Baud,^a Paul-Emmanuel Larchanché,^a Luc Buée,^a Jamal El Bakali,^{a*} Valérie Vingtdeux,^{a*} Nicolas Sergeant,^a Patricia Melnyk^a

^a *Université de Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France*

^b *Université de Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France*

^{\$} These authors contributed equally to this work

[#] Present address: Univ. Poitiers, CIC INSERM 1402, F-86073 Poitiers, France.

Abstract

Dysregulation of the Amyloid Precursor Protein (APP) processing leading to toxic species of amyloid β peptides ($A\beta$) is central to Alzheimer's disease (AD) etiology. $A\beta$ peptides are produced by sequential cleavage of APP by β -secretase (BACE-1) and γ -secretase. Lysosomotropic agent, chloroquine (CQ), has been reported to inhibit $A\beta$ peptide production. However, this effect is accompanied by an inhibition of lysosome-mediated degradation pathways. Following on from the promising activity of two series of APP metabolism modulators derived from CQ, we sought to develop new series of compounds that would retain the inhibitory effects on $A\beta$ production without altering lysosome functions. Herein, we applied a ligand-based pharmacophore modeling approach coupled with de novo design that led to the discovery of a series of biaryl compounds. Structure-activity relationship studies revealed that minor modifications like replacing a piperidine moiety of compound **30** by a cyclohexyl (compound **31**) allowed for the identification of compounds with the desired profile. Further studies have demonstrated that compounds **30** and **31** act through an indirect mechanism to inhibit β -secretase activity. This work shows that it is possible to dissociate the inhibitory effect on $A\beta$ peptide secretion of CQ-derived compounds from the lysosome-mediated degradation effect, providing a new profile of indirect β -secretase inhibitors.

Keywords:

Alzheimer's disease, Amyloid Precursor Protein, chloroquine, lysosome, autophagy, β -secretase, BACE-1, indirect inhibitor, phenotypic

1. Introduction

Alzheimer's disease (AD), the most frequent form of dementia, is characterized by a slow decline of cognitive and behavioral abilities. Two neuropathological lesions provide the definite diagnosis of AD: neurofibrillary tangles and amyloid deposits [1]. Neurofibrillary tangles are characterized by intraneuronal accumulation and aggregation of abnormally modified isoforms of the microtubule-associated tau proteins. Parenchymal amyloid deposits are composed of amyloid- β (A β) peptides, which derive from its precursor, the so-called amyloid precursor protein (APP) (for a comprehensive review see ref. [2]). Current treatments for AD remain symptomatic and provide only limited benefits to the patients. Therefore, alternative therapeutic options are urgently needed and over the past few years, much effort has been dedicated to the development of disease-modifying therapeutics [3]. One such strategy consists of reducing the levels of toxic species of A β peptides by targeting APP processing and more specifically secretases that cleave APP to produce A β peptides. Indeed, the metabolism of APP involves the action of several secretases and is sub-cellularly compartmentalized. APP is known to undergo proteolytic processing through two main pathways: the non-amyloidogenic pathway, initiated by α -secretase cleavage and the amyloidogenic pathway initiated by β -secretase cleavage (Figure 1) [4,5]. Both secretase-mediated steps release soluble ectodomains of APP (sAPP α and sAPP β) and membrane-bound carboxyl-terminal fragments (APP-CTFs), known as α CTF and β CTF. The latter are further cleaved by γ -secretase to give p3 and A β peptides, respectively, along with the APP intracellular domain (AICD).

Redirection of APP processing can be achieved either by blocking the amyloidogenic pathway or by promoting the non-amyloidogenic pathway. Because amyloidogenic processing is initiated by the cleavage of APP by β -secretase (β -site amyloid-precursor-protein-cleaving enzyme 1, BACE-1), this protease has been suggested as an attractive target to lower A β levels and the resulting amyloid plaques [6,7]. Recently, a mutation in APP (APP-A673T) that protects against the development of AD and age-related cognitive decline has been identified, providing further evidence that reducing β -secretase cleavage of APP may protect against AD [8,9]. Most efforts regarding β -secretase inhibitors have been focused on active site binders [10], and although β -secretase inhibitor drug development has proven challenging, several inhibitors are currently under clinical development [3,11]. Given that β -secretase has multiple substrates involved in important cellular and tissue functions, its inhibition may produce mechanism-based side effects [7]. As an alternative, a recent study showed that the anticancer drug Gleevec lowers A β levels through indirect inhibition of β -secretase processing of APP [12]. Another recent study taking advantage of the compartmentalization of APP processing,

showed that β -secretase inhibitors can be designed to specifically inhibit APP processing in the endosomal compartment with no effect on non-amyloid substrates [13]. Indeed, the endosomal/lysosomal compartments are known to be of importance for APP metabolism, APP degradation as well as for the production of A β peptides [14–16]. In this context, the lysosomotropic agent, chloroquine (CQ) has been reported to inhibit A β peptide production [17,18]. However, the alkalizing property of CQ also leads to the inhibition of lysosome-mediated degradation pathways, resulting in the accumulation of APP-CTFs and AICD [14,19,20], and in the disruption of the autophagic flux [21]. Autophagy-lysosomal pathway dysfunction has been suggested to play a detrimental role in the pathophysiology of AD [22–24]. Therefore, CQ-derived compounds that would maintain the effect on A β peptides without disrupting lysosomal functions would be of interest.

We have recently developed two series of compounds derived from either CQ (series A) or amodiaquine (AQ, series B) that demonstrated a strong inhibitory effect on both A β_{1-40} and A β_{1-42} secretions [17,25–28]. The lead compound of series A is currently ending phase I clinical trials. However, as observed for CQ, these effects were accompanied by a strong increase in the levels of α CTFs and AICD suggesting an alteration of lysosomal functions. Therefore, based on these earlier works, we sought to develop new series of compounds that would retain the effects on A β production without affecting α CTFs and AICD stabilities. To that purpose, in the absence of a defined molecular target of the previously developed compounds, a ligand-based pharmacophore modeling approach [29], coupled with *de novo* design was implemented. Herein, we describe a new series of compounds based on a biaryl scaffold decorated with amino side chains. Among these compounds, several were shown to inhibit A β peptides secretion and to promote α CTFs and AICD stabilities, as the parent compounds (series A and B). However, the structure activity relationship (SAR) study allowed for the discovery of compounds that kept the effect on A β peptides but had no impact on α CTFs and AICD stabilities. Further studies on two structurally very close compounds (**30** and **31**) with different profile regarding α CTFs and AICD stabilities suggest that an indirect β -secretase inhibitory effect can be achieved without the alkalizing property which is associated with the disruption of lysosomal functions.

2. Results and discussion

2.1. Ligand-based pharmacophore modeling

A ligand-based approach was applied to determine a common pharmacophoric model between the two series of compounds developed previously (Figure 2A). Because no model was able to predict compounds with the desired profile (decrease of A β peptides secretion with no impact

on α CTFs and AICD stabilities), the pharmacophore study took into account the sole inhibitory effect on A β production. Hence, a set of 51 compounds of series A [17,28] and 35 of series B [25,30] (Data and structures shown in Tables S1 and S2) was chosen regarding the ability of the compounds to inhibit A β_{1-42} secretion (subsequently named anti-A β). Compounds were classified into 4 classes: 2 (highly active), 1 (moderately active), 0 (inactive) and ND (not determined). The dominant and common property to all of the molecules is their high positive formal charge, which is comprised between +2 and +4. This ionization state could be ambiguous when predicted pKa get closer to physiological pH 7.4, in particular for both nitrogens of a piperazine group or for nitrogens of benzimidazole and quinoline heterocyclic moieties. In order to increase the possibility of pharmacophore detection on the basis of positively ionized features, the ionization state with the highest formal charge was selected for each molecule. 3D pharmacophore models were scored based on their ability to discriminate between active and inactive compounds (Table S3). The best model, describing four spatial points Positive/Positive/Positive/Aromatic (PPPA), was computed from the 18 molecules with the highest inhibitory activity of A β_{1-42} expression. This 3D pharmacophore model seemed more efficient in comparison with the 3-points PPA pharmacophores. Using the PPPA pharmacophoric model, several substructure were considered. This paper focuses on a biaryl-based series of compounds (Figure 2B). This biphenyl scaffold was substituted on the first phenyl ring by *N*-piperidinyloxy and 3-(*N*-piperidinyl)propanamino side chains and a benzylic tertiary amine in ortho position of the second phenyl ring. Structural modifications around this scaffold included, i) the modulation of the nature (piperidine, morpholine, dimethylamine and *N*-methylpiperazine) and the position (ortho, meta and para) of the benzylic tertiary amine, ii) the length of the linker separating the piperidine moieties from the first phenyl ring (*n*, *m* = 2 to 4), iii) replacement of the second phenyl group by a pyrrole, and iv) stepwise removal of the three tertiary amines.

2.2. Synthetic chemistry

Compounds **24-37** were obtained as described in Scheme 1. Commercially available benzoxazol-2-one was regioselectively brominated in position 6 (Br₂/AcOH), followed by *N*-alkylation, ring opening under alkaline conditions [31]. In this case, dioxane was used instead of MeOH to avoid side products. *O*-alkylation using NaH as a base gave intermediates **8-14** in moderate to good yields. Subsequent Suzuki-coupling reaction with appropriate boronic acids afforded compounds **15-23** and **37**. The last step consisted in a reductive amination, which was performed using two different procedures. Indeed, compounds **24-31** were obtained performing

the reaction in DCE and using $\text{NaBH}(\text{OAc})_3$ as the reductive agent (procedure A), while compounds **32–36** required the addition of titanium isopropoxide in EtOH and the use of NaBH_4 as the reductive agent (procedure B [32]).

Compounds **39**, **41** and **44** were obtained as described in Scheme 2. The first step consisted in a nucleophilic substitution (either *O*-alkylation or *N*-alkylation) followed by a Suzuki-coupling reaction to give compounds **39**, **40** and **43**. Subsequent reductive amination under procedure A afforded final compounds **41** and **44**.

Compound **51** was obtained as outlined in Scheme 3. Benzoxazol-2-one was first nitrated regioselectively in position 6 with nitric acid, followed by *N*-alkylation and ring opening under alkaline conditions to give intermediate **47**. Subsequent *O*-alkylation using K_2CO_3 as a base, and nitro reduction with ammonium formate gave **49**. The latter was subjected to a Clauson-Kaas reaction with 2,5-dimethoxy-3-tetrahydrofurancarboxaldehyde in acetic acid to form pyrrole intermediate **50** [33]. The last step consisted in a reductive amination in DCE and using $\text{NaBH}(\text{OAc})_3$ as the reductive agent to give compound **51**.

2.3. Structure-Activity Relationship studies

Final compounds were evaluated for their ability to modulate APP processing on SY5Y human neuroblastoma cell line stably expressing the neuronal isoform of human wild-type APP⁶⁹⁵ (SY5Y-APPwt). $\text{A}\beta$ levels ($\text{A}\beta_{1-40}$ and $\text{A}\beta_{1-42}$) after treatment with reference and tested compounds were measured by ELISA (Table 1). Results are expressed as IC_{50} values which correspond to the concentration of a given compound that inhibits $\text{A}\beta$ expression by 50% (either $\text{A}\beta_{1-40}$ or $\text{A}\beta_{1-42}$). APP carboxy-terminal fragments (αCTFs and AICD) levels were assessed by Western-blotting (WB). The effect of reference and tested compounds on αCTFs and AICD are expressed as the intensity of corresponding WB bands. Compounds effect was measured at various concentrations (1, 3, 10 μM , Figure 3) and compared to the effect of CQ at 3 μM (Table 1). First, when considering the effect on $\text{A}\beta$ levels, regardless of the modulations, all synthesized compounds decreased $\text{A}\beta$ levels with IC_{50} values ranging from 1.2 to 13.7 μM . While compound **39** ($\text{A}\beta_{1-40}$: $\text{IC}_{50} = 9.1 \mu\text{M}$ and $\text{A}\beta_{1-42}$: $\text{IC}_{50} = 13.7 \mu\text{M}$) displayed similar activity to CQ ($\text{A}\beta_{1-40}$: $\text{IC}_{50} = 7.0 \mu\text{M}$ and $\text{A}\beta_{1-42}$: $\text{IC}_{50} = 12.7 \mu\text{M}$), all other evaluated compounds were found to be more active (IC_{50} ranging from 1.2 to 5.2 μM). The different modulations applied, including the modification of the position of the piperidine borne by the second phenyl group (compare **24**, **26** and **27**), the replacement of the piperidine by other tertiary amines (compare **24** vs **25** and **26–29**) and the modification of the length of both piperidine alkyl chains on the other side of the molecule (**30** vs **32–36**) had little impact on $\text{A}\beta$

levels. Finally, replacing one of the phenyl rings of **30** ($A\beta_{1-40}$: $IC_{50} = 2.8 \mu M$ and $A\beta_{1-42}$: $IC_{50} = 3.4 \mu M$) with a pyrrole (compound **51**) led to a two-fold decrease in activity ($A\beta_{1-40}$: $IC_{50} = 5.0 \mu M$ and $A\beta_{1-42}$: $IC_{50} = 6.5 \mu M$). The main factor that appears to influence this activity is the number of tertiary amines. Indeed, **41** (two tertiary amines, $A\beta_{1-40}$: $IC_{50} = 1.5 \mu M$ and $A\beta_{1-42}$: $IC_{50} = 1.2 \mu M$) was 10-fold more active than **39** (one tertiary amine, $A\beta_{1-40}$: $IC_{50} = 9.1 \mu M$ and $A\beta_{1-42}$: $IC_{50} = 13.7 \mu M$), while adding an extra tertiary amine did not improve activity (e.g. compare **41**, $A\beta_{1-40}$: $IC_{50} = 1.5 \mu M$ and $A\beta_{1-42}$: $IC_{50} = 1.2 \mu M$ and **33**, $A\beta_{1-40}$: $IC_{50} = 1.4 \mu M$ and $A\beta_{1-42}$: $IC_{50} = 1.2 \mu M$). Hence, with regard to $A\beta$ levels, two basic centers are required in this series to get an efficient inhibitory activity. Interestingly, compounds displaying one or two tertiary amines had little (**41** and **44**) or no impact (**31** and **39**) on AICD and α CTFs stabilities while compounds with three tertiary amines significantly promote AICD and α CTFs stabilities. Indeed, as can be seen from Table 1 and Figures 2A and 2B, compounds displaying three tertiary amines (**24-30**, **32-36** and **51**) were all more potent than CQ ($3 \mu M$) in increasing AICD and α CTFs levels (up to 6 fold, Table 1). For example, compared to control conditions, compound **30** and **32** ($3 \mu M$) increased α CTFs levels by almost 30 and 50-fold, respectively and AICD levels by more than 40 and 30-fold, respectively. On the other hand, replacing one piperidine of compound **30** by a cyclohexyl group (**31**) completely abolished AICD and α CTFs activities as compound **31** had a similar profile as the untreated conditions. This result shows that it is possible to retain the effects on $A\beta$ secretion without affecting α CTFs and AICD stabilities and encouraged us to further refine APP processing profile of compounds **30** and **31**.

2.4 Effects of compounds **30** and **31** on APP metabolism

Following this primary screening and structure activity relationship analysis, a detailed and comparative analysis of compounds **30** and **31** was performed. First, toxicity assays were performed with both compounds on SY5Y-APPwt cells and in primary neurons. Compounds were tested up to $5 \mu M$ and no toxicity was observed (Figure S1). Effects of both compound was then assessed simultaneously on APP metabolism. Full-length APP proteins were resolved and detected with the APP-C17 antiserum as two bands at 110 kDa and 115 kDa. The lowest APP band corresponds to the neosynthesized or immature form of APP whereas the highest band corresponds to the glycosylated, namely the mature form of APP. Both were quantified, and no modification of immature APP levels was observed with either compounds (Figure 4A, D and F). While compound **31** did not modify the expression of mature APP, compound **30** significantly increased mature APP expression at $5 \mu M$ by 221% (Figure 4A, C and E). These results were confirmed using primary neuronal cultures in which treatment with compound **30**

at 3 and 5 μ M induced a significant increase in mature APP of 130% when compared to the control condition (Figure S2A, C). In primary neurons, compound **31** had also no effect on total APP expression (Figure S2A, E).

Full-length APP is further processed by α -, β - and γ -secretases to generate APP-CTFs and AICD. A significant accumulation of APP-CTFs and AICD was observed following treatment with compound **30** (Figure 4B, G, H). This accumulation of APP-CTFs was also observed in primary neurons (Figure S2A and D). Surprisingly, compound **31** did not demonstrate any effect on APP-CTFs or AICD expression in both SY5Y-APPwt cells and primary neuronal cultures (Figure 4B, I, J and Figure S3A, F).

As shown previously (Table 1), compounds **30** and **31** significantly reduced $A\beta_{1-40}$ and $A\beta_{1-42}$ production (Figure 4K-N). This reduction of $A\beta$ production may be caused by either an increase of the α -secretase cleavage or a decrease of either the β - or γ -secretase cleavage of APP. Thus, we assessed the secretion of sAPP α and sAPP β , which are the shedded byproducts of α - and β -secretase, respectively. Both compounds **30** and **31** were found to significantly reduce sAPP β concentration (Figure 4P and R). On the opposite, sAPP α concentration was significantly increased by compound **30** and to a lesser extend by compound **31** (Figure 4O and Q). Together these results strongly suggest that compounds **30** and **31** reduce $A\beta_{1-40}$ and $A\beta_{1-42}$ secretion by repressing β -secretase cleavage of APP while increasing the secretion of sAPP α .

To determine whether compounds **30** and **31** were direct BACE-1 inhibitors, an enzymatic assay monitoring the cleavage of a fluorogenic peptide substrate (Mca-S-E-V-N-L-D-AE-F-R-K(Dnp)-R-R-NH₂) was performed [34]. In contrast to reference OM 99-2 (IC₅₀ = 59 nM), under the assay conditions (cf. experimental section), neither compound **30** nor **31** inhibited the cleavage of the fluorogenic peptide even at a concentration of 10 μ M (% inhibition < 10%). All together, these data show that compounds **30** and **31** are acting through an indirect mechanism to inhibit β -secretase activity.

Although compounds **30** and **31** derived from the same pharmacophore, only compound **30** increased the expression of mature APP, APP-CTFs and AICD, suggesting that compounds **30** and **31** operated through different mechanisms. CQ is a well-known inhibitor of the autophagic flux and lysosomal degradation pathway, and compounds of series A derive from a CQ library of molecules. Therefore, we assessed whether the activity of compound **30** involved a repression of lysosomal activities that could explain the observed accumulation of mature APP, APP-CTFs and AICD. To address this question, we studied the effect of both compounds **30** and **31** on the autophagic flux. To that purpose, we assessed two markers associated with autophagy: p62 and LC3-I lipidation into LC3-II, which is characterized by the appearance of

a second band at 14 kDa under the LC3-I band of 18 kDa. Treatment with compound **30** at 5 μ M induced an increase of p62 expression by 476% as compared to the control condition (Figure 5A and B). LC3-I lipidation into LC3-II was also increased by 591% (Figure 5A and D). Similar results were obtained in primary neurons starting at a concentration of 3 μ M of compound **30** (Figure S2B, G and H). In sharp contrast, compound **31** showed no effect on these two autophagy markers in either cell systems (Figure 5A, C, E and Figure S3B, I and J). As the increase of p62 and LC3 lipidation suggest an inhibition of the autophagic flux, we co-treated the cells with compound **30** and Bafilomycin A1 (BafA1), a well-known inhibitor of the autophagic flux [35]. In co-treatment with BafA1, compound **30** demonstrated similar accumulations of p62 and LC3-II as with BafA1 alone (Figure 5F, G and H). Indeed, no additive effect of co-treatments was observed for p62 expression or LC3 lipidation, showing that compound **30** display an inhibitory effect on the autophagic flux. Inhibition of the autophagic flux and accumulation of p62 and LC3 were further confirmed by immunofluorescence in SY5Y-APPwt cells (Figure 5I and J) and in primary neurons (Figure S2K and L). Treatment with compound **30** at 5 μ M displayed a significant accumulation of p62 and LC3 positive vesicles inside these two different cell models. Together, these results demonstrate that compound **30** acts as an inhibitor of the autophagic flux, and thus of lysosomal degradation properties. Importantly, compound **31**, which displays a similar activity than compound **30** toward A β reduction, does not bear this later property.

3. Conclusion

This work reports the design, synthesis and in vitro biological evaluation of a biaryl-based series of modulators of APP processing. SAR studies revealed that all compounds were able to decrease A β secretion but minor modifications like replacing a piperidine moiety of **30** by a cyclohexyl (compound **31**) totally abolished AICD and α CTFs stabilities. The effect of compound **30** and related analogues on AICD and α CTFs stabilities was shown to be linked to an alteration of lysosomal functions. Compound **31**, on the other hand, behave as an indirect β -secretase inhibitor with no effect on lysosomes. Importantly, this work shows that it is possible to dissociate the lysosomotropic effect of CQ-derived compounds from their action on A β secretion, providing a new profile of indirect β -secretase inhibitors. Although the exact mechanism of action remains to be elucidated, this novel series provides an opportunity for the development of novel β -secretase inhibitors potentially useful for the treatment of AD.

4. Experimental sections

4.1. Chemistry

The reaction monitoring was performed by thin layer chromatography (TLC) on Macherey-Nagel Alugram® Sil 60/UV254 (thickness 0.2 mm). TLC were revealed by UV ($\lambda = 254$ nm) and/or the appropriate stain (iodine, ninydrine). Purification of the compounds was carried out by column chromatography (either flash or manual). Manual chromatography was performed using Macherey-Nagel silica gel (0.04-0.063 mm of particle size). Flash chromatography was performed on a Reveleris® Flash Chromatography System using Macherey-Nagel Chromabond flash RS columns. NMR spectra were recorded on a Bruker DRX 300 spectrometer (operating at 300 MHz for ^1H and 75 MHz for ^{13}C). Chemical shifts are reported in parts per million (ppm) relative to an internal reference (either tetramethylsilane or residual deuterated solvents ^1H signals). Each signal is reported with its chemical shift (δ), multiplicity (s = singulet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad), coupling constant (J in Hz, when applicable) and relative integral. The attributions of protons and carbons were achieved by analysis of 1D and 2D experiments (^1H , ^{13}C , COSY, HQC and HMBC). LC-MS were performed on a Varian triple quadrupole 1200W mass spectrometer equipped with a non-polar C18 TSK-gel Super ODS (4.6 x 50 mm) column, using electrospray ionisation and a UV detector (diode array). Elution was performed at a flow rate of 2 mL/min with water-formic acid (pH = 3.8) as eluent A and ACN-formic acid (pH = 3.8) as eluent B, employing a 0.25 min plateau with 0 % B and a linear gradient from 0 % B to 98 % B in 3.25 min, followed by a 0.5 min plateau with 98 % B. Then, column re-equilibration was performed for 1 min. HRMS were recorded on a Hight Resolution Mass Spectrometer (HRMS) Thermo Scientific™ Exactive™. Analysed compounds were dissolved in methanol and directly injected in the ionisation source ESI, in positive or negative mode according to the analyzed compound, and recorded for one minute. The Xcalibur software was used to determine the elemental composition of main pics of the spectrum. The purity of final compounds was determined by high pressure liquid chromatography (HPLC) using two columns: C18 Interchrom UPTISPHERE and C4 Interchrom UPTISPHERE. The HPLC analysis was carried out on a Shimadzu LC-2010AHT system equipped with a UV detector set at 254 and 215 nm. The compounds were dissolved in 100 μL of buffer B and 900 μL of buffer A. The eluent system used was: buffer A ($\text{H}_2\text{O}/\text{TFA}$, 100:0.1) and buffer B (ACN/ $\text{H}_2\text{O}/\text{TFA}$, 80:20:0.1). Retention times (t_r) were obtained at a flow rate of 0.2 mL/min for 37 min using a gradient from 100% of buffer A over 1 min, to 100 % buffer B over the next 30 min, to 100% of buffer A over 1 min and 100% of buffer A over 1

min. All tested compounds showed a purity of $\geq 95\%$. The melting point analyses were performed on Barnstead Electrothermel Melting Point Series IA9200 and were not corrected. All final compounds were transformed into their hydrochloride salt forms (before testing) using the following procedure: the compound was dissolved in MeOH and 2N HCl_{aq} was added dropwise until pH1. The solvent was evaporated and the compound was freeze-dried.

6-Bromo-3*H*-1,3-benzoxazol-2-one (**1**)

3*H*-1,3-Benzoxazol-2-one (5.00 g, 37.00 mmol) was dissolved in acetic acid (50 mL) and bromine (1.9 mL, 37.0 mmol) was added dropwise. The reaction mixture was stirred at 20 °C for 4 h. The reaction mixture was poured onto ice and the precipitate was collected by filtration, washed with water and air-dried to give a pink powder (7.48 g, 34.8 mmol, 94%). Mp 191.6 – 192.3 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.81 (s, 1H), 7.57 (dd, *J* = 1.9 Hz, *J* = 0.3 Hz, 1H), 7.30 (dd, *J* = 8.3 Hz, *J* = 1.9 Hz, 1H), 7.04 (dd, *J* = 8.3 Hz, *J* = 0.3 Hz, 1H). ¹³C NMR (75 MHz, DMSO-*d*₆): δ 154.5, 144.5, 130.3, 126.9, 113.5, 113.2, 111.7. LCMS *m/z* calc for [M-H]⁺: 211.9, 213.9, found: 211.8, 213.8.

General procedure for the synthesis of compounds 2 and 3. 6-bromo-3*H*-1,3-benzoxazol-2-one **1** (5.00 g, 23.36 mmol) was suspended in ACN (150 mL) and K₂CO₃ (9.69 g, 70.09 mmol) was added. The reaction mixture was stirred at 80 °C for 30 min. 1-(2-Chloroethyl)piperidine hydrochloride (4.30 g, 23.36 mmol) or 3-chloropropylpiperidine hydrochloride (5.5 g, 28 mmol) was added and the reaction mixture was stirred at 80 °C for another 12 h. The inorganics were removed by filtration and the solvent was evaporated. The residue was purified by flash chromatography (DCM/MeOH(NH₃), 9.8:0.2 (v/v)) to afford compounds **2** and **3**.

6-Bromo-3-[2-(piperidin-1-yl)ethyl]-1,3-benzoxazol-2-one (**2**)

Beige solid (7.58 g, 23.1 mmol, 99 %). Mp 85.1– 85.8 °C. ¹H NMR (300 MHz, CDCl₃): δ 7.36 (d, *J* = 1.8 Hz, 1H), 7.31 (dd, *J* = 8.3, 1.8 Hz, 1H), 6.92 (d, *J* = 8.3 Hz, 1H), 3.90 (t, *J* = 6.6 Hz, 2H), 2.64 (t, *J* = 6.6 Hz, 2H), 2.51 – 2.38 (m, 4H), 1.60 – 1.35 (m, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 154.1, 143.1, 130.7, 126.6, 114.4, 113.5, 109.9, 56.0, 54.7, 40.3, 26.0, 24.2. LCMS *m/z* calc for [M+H]⁺: 325.1, 327.1 found: 325.1, 327.1.

6-Bromo-3-[3-(piperidin-1-yl)propyl]-1,3-benzoxazol-2-one (**3**)

Colorless oil (7.76 g, 22.9 mmol, 98%). ¹H NMR (300 MHz, CDCl₃): δ 7.36 (d, *J* = 1.8 Hz, 1H), 7.30 (dd, *J* = 8.3 Hz, *J* = 1.8 Hz, 1H), 6.98 (d, *J* = 8.3 Hz, 1H), 3.88 (t, *J* = 6.7 Hz, 2H);

2.35 – 2.28 (m, 6H), 1.98 – 1.89 (m, 2H), 1.60 – 1.51 (m, 4H), 1.46 – 1.38 (m, 2H). ^{13}C NMR (75 MHz, CDCl_3): δ 154.1, 143.1, 130.8, 126.6, 114.4, 113.5, 109.7, 55.5, 54.5, 40.6, 25.9, 24.8, 24.4. LCMS m/z calc for $[\text{M}+\text{H}]^+$: 338.1, 340.1, found: 338.9, 340.8.

6-bromo-3-[4-(piperidin-1-yl)butyl]-1,3-benzoxazol-2-one (**4**)

To a solution of 1-bromo-4-chlorobutane (2.17 mL, 18.7 mmol), K_2CO_3 (3.87 g, 28.04 mmol) in ACN (1 mL) was added dropwise at a solution of 6-bromo-3*H*-1,3-benzoxazol-2-one (**1**) in ACN (3 mL). The mixture was heated at 80 °C for 12 h. The inorganics were removed by filtration and the solvent was evaporated. The residue was purified by column chromatography (cyclohexane/ethyl acetate, 9:1 (v:v)) to afford 6-bromo-3-(4-chlorobutyl)-1,3-benzoxazol-2-one as a white solid (1.2 g, 3.94 mmol). Mp 61.9 – 62.4 °C. ^1H NMR (300 MHz, CDCl_3): δ 7.39 (d, J = 1.8 Hz, 1H), 7.34 (dd, J = 8.3, 1.8 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H), 3.87 (t, J = 6.8 Hz, 2H), 3.60 (t, J = 6.1 Hz, 2H), 2.27 – 1.74 (m, 4H). ^{13}C NMR (75 MHz, CDCl_3): δ 154.1, 143.1, 130.2, 126.9, 114.8, 113.8, 109.2, 77.5, 77.0, 76.6, 44.0, 41.6, 29.2, 25.0. LCMS m/z calc for $[\text{M}+\text{ACN}+\text{H}]^+$: 345.6, 347.6, found: 345.1, 347.1.

6-Bromo-3-(4-chlorobutyl)-1,3-benzoxazol-2-one (1.2 g, 3.94 mmol) was dissolved in piperidine (19 mL) and refluxed for 12 h. The mixture was concentrated *in vacuo* and the residue was dissolved in 1N NaOH (20 mL) and extracted with DCM (3 x 60 mL). The combined organic layers were dried over MgSO_4 , filtrated and concentrated *in vacuo*. The residue was purified by column chromatography (DCM/MeOH(NH_3), 9.5 :0.5 (v:v)) to afford a beige powder (1.07 g, 3.0 mmol, 16% over two steps). Mp 100.2 – 101.0 °C. ^1H NMR (300 MHz, CDCl_3): δ 7.37 (d, J = 1.8 Hz, 1H), 7.32 (dd, J = 8.3, 1.8 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H), 3.83 (t, J = 7.2 Hz, 2H), 2.38 – 2.27 (m, 6H), 1.86 – 1.70 (m, 2H), 1.66 – 1.42 (m, 8H). ^{13}C NMR (75 MHz, CDCl_3): δ 154.0, 143.1, 130.4, 126.7, 114.6, 113.6, 109.4, 58.5, 58.4, 54.6, 42.3, 42.2, 30.0, 25.8, 24.4, 23.9. LCMS m/z calc for $[\text{M}+\text{H}]^+$: 353.1, 355.1, found: 353.1, 355.1.

General procedure for the synthesis of compounds 5-7 is exemplified by the protocol used for the synthesis of 5. To a solution of 6-bromo-3-[2-(piperidin-1-yl)ethyl]-1,3-benzoxazol-2-one (**2**) (4.0 g, 12.3 mmol) in dioxane (19 mL), aqueous 2.5N NaOH (98.4 mL, 246 mmol) was added. The mixture was stirred at 20 °C for 12 h. After cooling to 0 °C, a 1N HCl solution was added to reach pH 8. After 30 min of stirring, the mixture was extracted with DCM (3 x 100 mL). The combined organic layers were dried over MgSO_4 and evaporated to afford 5-bromo-2-((2-(piperidin-1-yl)ethyl)amino)phenol **5** as a beige solid (3.1 g, 10.4 mmol, 84%) that was

used without further purification. Mp 126.8 – 127.5 °C. ¹H NMR (300 MHz, CDCl₃): δ 6.95 (d, *J* = 2.1 Hz, 1H), 6.87 (dd, *J* = 8.3, 2.1 Hz, 1H), 6.66 (d, *J* = 8.3 Hz, 1H), 3.25 – 3.15 (t, *J* = 5.7 Hz, 2H), 2.60 – 2.31 (m, 6H), 1.75 – 1.64 (m, 4H), 1.56 – 1.45 (m, 2H). ¹³C NMR (75 MHz, CDCl₃): δ 151.1, 135.8, 122.7, 120.9, 119.8, 113.8, 57.3, 54.3, 44.7, 25.0, 23.9. LCMS *m/z* calc for [M+H]⁺: 299.1, 301.1, found: 299.1, 301.1.

5-Bromo-2-([3-(piperidin-1-yl)propyl]amino)phenol (6)

Brown oil (2.16 g, 6.9 mmol, 95%). ¹H NMR (300 MHz, MeOD): δ 6.82 – 6.78 (m, 2H), 6.49 (d, *J* = 8.1 Hz, 1H), 3.15 (t, *J* = 6.7 Hz, 2H), 2.57 – 2.52 (m, 6H), 1.89 – 1.80 (m, 2H), 1.69 – 1.62 (m, 4H), 1.54 – 1.50 (m, 2H). ¹³C NMR (75 MHz, MeOD): δ 145.8, 136.7, 122.1, 115.9, 111.5, 107.6, 56.7, 53.9, 41.8, 25.0, 24.7, 23.4. LCMS *m/z* calc for [M+H]⁺: 313.1, 315.1, found: 312.9, 314.9.

5-bromo-2-[(4-(piperidin-1-yl)butyl)amino]phenol (7)

Beige solid (246 mg, 0.75 mmol, 50%). Mp 130.3 – 130.9 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 6.79 – 6.73 (m, 2H), 6.40 (d, *J* = 9.0 Hz, 1H), 3.02 (t, *J* = 6.5 Hz, 2H), 2.39 – 2.22 (m, 6H), 1.59 – 1.27 (m, 12H). ¹³C NMR (75 MHz, DMSO-*d*₆): δ 145.2, 137.1, 121.9, 115.7, 110.6, 105.4, 58.0, 53.9, 42.5, 40.3, 40.1, 39.8, 39.5, 39.2, 39, 38.7, 26.3, 25.4, 24.0, 23.8. LCMS *m/z* calc for [M+H]⁺: 327.1, 329.1 found: 327.2, 329.2.

General procedure for the synthesis of compounds 8, 9, 11-14 is exemplified by the protocol used for the synthesis of 8. To a solution of 5-bromo-2-([2-(piperidin-1-yl)ethyl]amino)phenol (**5**) (550 mg, 1.84 mmol) in DMF (23 mL), at 0 °C, NaH (147 mg, 3.68 mmol) was added. After stirring the mixture for 30 min, 1-(2-chloroethyl)piperidine hydrochloride (338 mg, 1.84 mmol) was added at 0 °C. The reaction mixture was stirred for another 12 h at rt. The mixture was diluted with 20 mL of water and extracted with DCM (3 x 60 mL). The combined organic layers were dried over MgSO₄ and evaporated. The residue was purified by column chromatography (DCM/MeOH(NH₃), 9.5:0.5 (v:v)) to afford 4-bromo-2-(2-(piperidin-1-yl)ethoxy)-*N*-(2-(piperidin-1-yl)ethyl)aniline (**8**) as a brown oil (587 mg, 1.43 mmol, 78 %). ¹H NMR (300 MHz, CDCl₃): δ 6.96 (dd, *J* = 8.4, 1.9 Hz, 1H), 6.86 (d, *J* = 1.9 Hz, 1H), 6.43 (d, *J* = 8.4 Hz, 1H), 4.91 (s, 1H), 4.10 (t, *J* = 5.8 Hz, 2H), 3.22 – 3.05 (m, 2H), 2.82 (t, *J* = 5.8 Hz, 2H), 2.68 – 2.34 (m, 10H), 1.71 – 1.52 (m, 8H), 1.51 – 1.39 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 146.9, 138.0, 124.0, 114.1, 110.8, 107.3, 66.7, 58.0, 57.3, 54.9, 54.4, 40.3, 26.1, 26.0, 24.5, 24.2. LCMS *m/z* calc for [M+H]⁺: 410.4, 412.4 found: 410.2, 412.2.

4-Bromo-*N*-[2-(piperidin-1-yl)ethyl]-2-[3-(piperidin-1-yl)propoxy]aniline (**9**)

Brown oil (450 mg, 1.06 mmol, 32 %). ¹H NMR (300 MHz, CDCl₃): δ 6.95 (dd, *J* = 8.4, 2.1 Hz, 1H), 6.85 (d, *J* = 2.1 Hz, 1H), 6.43 (d, *J* = 8.4 Hz, 1H), 4.81 (t, *J* = 5.0 Hz, 1H), 4.01 (t, *J* = 6.2 Hz, 2H), 3.14 (m, 2H), 2.69 – 2.25 (m, 12H), 2.11 – 1.91 (m, 2H), 1.73 – 1.31 (m, 12H). ¹³C NMR (75 MHz, CDCl₃): δ 147.0, 137.8, 123.7, 113.7, 110.8, 107.5, 67.1, 57.5, 57.2, 56.1, 54.7, 40.3, 26.8, 26.1, 25.9, 24.4. LCMS *m/z* calc for [M+H]⁺: 424.2, 426.2 found: 424.3, 426.2.

4-Bromo-2-[2-(piperidin-1-yl)ethoxy]-*N*-[3-(piperidin-1-yl)propyl]aniline (**11**)

Brown oil (2.30 g, 5.42 mmol, 79 %). ¹H NMR (300 MHz, CDCl₃): δ 6.95 (dd, *J* = 8.4 Hz, *J* = 2.2 Hz, 1H), 6.86 (d, *J* = 2.2 Hz, 1H), 6.45 (d, *J* = 8.4 Hz, 1H), 4.73 (br s, 1H), 4.09 (t, *J* = 6.2 Hz, 2H), 3.13 (t, *J* = 6.7 Hz, 2H), 2.76 (t, *J* = 6.1 Hz, 2H), 2.51 – 2.36 (m, 10H), 1.88 – 1.79 (m, 2H), 1.64 – 1.57 (m, 8H), 1.49-1.41 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 146.2, 138.1, 124.1, 114.4, 110.7, 107.2, 66.6, 57.9, 57.4, 54.8, 42.5, 26.3, 26.0, 24.3. LCMS *m/z* calc for [M+H]⁺: 424.2, 426.2, found: 424.3, 426.2

4-Bromo-2-(3-(piperidin-1-yl)propoxy)-*N*-(3-(piperidin-1-yl)propyl)aniline (**12**)

Brown oil (940 mg, 2.1 mmol, 56 %). ¹H NMR (300 MHz, CDCl₃): δ 6.94 (dd, *J* = 8.4, 2.1 Hz, 1H), 6.85 (d, *J* = 2.1 Hz, 1H), 6.44 (d, *J* = 8.4 Hz, 1H), 4.55 (s, 1H), 4.01 (t, *J* = 6.4 Hz, 2H), 3.22 – 3.03 (m, 2H), 2.55 – 2.20 (m, 12H), 2.07 – 1.95 (m, 2H), 1.90 – 1.76 (m, 2H), 1.70 – 1.55 (m, 8H), 1.50 – 1.40 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 146.7, 137.7, 123.7, 113.7, 110.6, 107.3, 67.1, 57.4, 55.9, 54.7, 54.6, 42.4, 29.7, 26.8, 26.3, 25.9, 24.4. LCMS *m/z* calc for [M+H]⁺: 438.2, 440.2, found: 438.3, 440.2.

4-Bromo-*N*-[4-(piperidin-1-yl)butyl]-2-[2-(piperidin-1-yl)ethoxy]aniline (**13**)

Brown oil (513 mg, 1.17 mmol, 55 %). ¹H NMR (300 MHz, CDCl₃): δ 6.96 (dd, *J* = 8.4, 2.1 Hz, 1H), 6.87 (d, *J* = 2.1 Hz, 1H), 6.44 (d, *J* = 8.4 Hz, 1H), 4.37 (s, 1H), 4.08 (t, *J* = 5.9 Hz, 2H), 3.12 (s, 2H), 2.76 (t, *J* = 5.9 Hz, 2H), 2.58 – 2.27 (m, 10H), 1.78 – 1.36 (m, 16H). ¹³C NMR (75 MHz, CDCl₃): δ 146.5, 138, 124.2, 114.6, 110.7, 107.1, 66.8, 59.1, 57.9, 55, 54.6, 43.5, 27.4, 26.0, 24.5, 24.2. LCMS *m/z* calc for [M+H]⁺: 438.2, 440.2, found 438.3, 440.3.

4-Bromo-2-(2-cyclohexylethoxy)-*N*-(3-(piperidin-1-yl)propyl)aniline (**14**)

Brown oil (80 mg, 0.19 mmol, 59 %). ¹H NMR (300 MHz, CDCl₃): δ 6.96 (dd, *J* = 8.4 Hz, *J* = 2.1 Hz, 1H), 6.83 (d, *J* = 2.1 Hz, 1H), 6.45 (d, *J* = 8.4 Hz, 1H), 3.99 (t, *J* = 6.75 Hz, 2H), 3.13

(t, J = 6.6 Hz, 2H), 2.47 – 2.43 (m, 6H), 1.90 – 1.60 (m, 13H), 1.50 – 1.44 (m, 3H), 1.25 – 1.22 (m, 3H), 1.04 – 0.97 (m, 2H). ^{13}C NMR (75 MHz, CDCl_3): δ 146.9, 137.9, 123.5, 113.5, 110.5, 107.4, 66.6, 57.3, 54.7, 42.5, 36.5, 34.8, 33.3, 26.5, 26.2, 26.1, 25.7, 24.3. LCMS m/z calc for $[\text{M}+\text{H}]^+$: 423.2, 425.2, found: 423.2, 425.0.

4-Bromo-2-(4-chlorobutoxy)-*N*-(2-(piperidin-1-yl)ethyl)aniline (**10**)

To a solution of 5-bromo-2-([2-(piperidin-1-yl)ethyl]amino)phenol (**5**) (1 g, 3.34 mmol) in DMF (42 mL), at 0 °C, NaH (334 mg, 8.36 mmol) was added. After stirring the mixture for 30 min, 1-bromo-4-chlorobutane (0.43 ml, 3.34 mmol) in DMF (5 ml) was added dropwise at 0 °C. The reaction mixture was stirred for another 12 h at rt. The mixture was diluted with 40 mL of water and extracted with DCM (3 x 60 mL). The combined organic layers were dried over MgSO_4 and evaporated. The residue was purified by column chromatography (DCM/MeOH(NH_3), 9.8 :0.2 (v:v)) to afford 4-bromo-2-(4-chlorobutoxy)-*N*-(2-(piperidin-1-yl)ethyl)aniline as a colorless oil (450 mg, 1.15 mmol). ^1H NMR (300 MHz, CDCl_3): δ 6.97 (dd, J = 8.3, 2.1 Hz, 1H), 6.84 (s, 1H), 6.44 (dd, J = 8.3, 1.5 Hz, 1H), 4.88 (s, 1H), 4.06 – 3.97 (m, 2H), 3.70 – 3.58 (m, 2H), 3.21 – 3.07 (m, 2H), 2.61 (t, J = 5.2 Hz, 2H), 2.48 – 2.35 (m, 4H), 2.12 – 1.94 (m, 4H), 1.68 – 1.44 (m, 6H). ^{13}C NMR (75 MHz, CDCl_3): δ 146.8, 137.9, 123.9, 113.6, 110.9, 107.4, 67.4, 57.1, 54.3, 44.7, 40.2, 29.4, 26.7, 26.2, 24.5. LCMS m/z calc for $[\text{M}+\text{H}]^+$: 389.1, 391.1, 393.1, found: 389.1, 391.1, 393.2.

4-Bromo-2-(4-chlorobutoxy)-*N*-(2-(piperidin-1-yl)ethyl)aniline (438 mg, 1.12 mmol) was dissolved in piperidine (11 mL) and was refluxed for 12 h. The mixture was concentrated *in vacuo* and the residue was dissolved in 1N NaOH (20 mL) and extracted with DCM (3 x 60 mL). The combined organic layers were dried over MgSO_4 , filtrated and concentrated *in vacuo*. The residue was purified by column chromatography (DCM/MeOH(NH_3), 9.8 :0.2 (v:v)) to afford **10** as a brown oil (246 mg, 0.56 mmol, 18% over two steps). ^1H NMR (300 MHz, CDCl_3): δ 6.95 (dd, J = 8.4, 2.1 Hz, 1H), 6.83 (d, J = 2.1 Hz, 1H), 6.43 (d, J = 8.4 Hz, 1H), 4.81 (s, 1H), 3.98 (t, J = 6.3 Hz, 2H), 3.27 – 2.98 (m, 2H), 2.60 (t, J = 6.3 Hz, 2H), 2.49 – 2.27 (m, 10H), 2.00 – 1.78 (m, 2H), 1.76 – 1.52 (m, 10H), 1.50 – 1.39 (m, 4H). ^{13}C NMR (75 MHz, CDCl_3): δ 147.0, 137.9, 123.6, 113.6, 110.7, 107.5, 68.3, 59.0, 57.2, 54.6, 54.4, 40.8, 27.5, 26.2, 25, 24.5, 23.5. LCMS m/z calc for $[\text{M}+\text{H}]^+$: 438.2, 439.2, found: 438.3, 440.3.

General procedure for the synthesis of compounds 15-23 is exemplified by the protocol used for the synthesis of 15. 2-Formylbenzeneboronic acid (63 mg, 0.42 mmol) was dissolved in a mixture of toluene (8 mL) and EtOH (3.2 mL). K_2CO_3 (62 mg, 0.45 mmol) and 4-bromo-

2-[2-(piperidin-1-yl)ethoxy]-*N*-[3-(piperidin-1-yl)propyl]aniline (**11**) (150 mg, 0.35 mmol) were added and the reaction was stirred for 30 min and deoxygenated by passing a stream of N₂ through it. Pd₂dba₃ (7 mg, 0.01 mmol) and P(*o*-tol)₃ (22 mg, 0.07 mmol) were added and the mixture was refluxed for 18 h. After cooling to rt, the mixture was poured into water, extracted with ethyl acetate. The combined organic layers were dried over MgSO₄ and evaporated. The residue was purified by flash chromatography (PE/EtOAc/MeOH(NH₃), 10:0:0 to 5.2:4.4:0.4 (v/v)) to afford 3'-(2-(piperidin-1-yl)ethoxy)-4'-((3-(piperidin-1-yl)propyl)amino)-[1,1'-biphenyl]-2-carbaldehyde (**15**) as a brown oil (146 mg, 0.32 mmol, 92%). ¹H NMR (300 MHz, CDCl₃): δ 10.03 (s, 1H), 7.99 – 7.96 (m, 1H); 7.62 – 7.58 (m, 1H); 7.47 – 7.38 (m, 2H), 6.87 (dd, *J* = 7.9 Hz, *J* = 1.9 Hz, 1H), 6.82 (d, *J* = 1.9 Hz, 1H), 6.67 (d, *J* = 7.9 Hz, 1H), 4.98 (br s, 1H), 4.16 (t, *J* = 6.1 Hz, 2H), 3.25 (t, *J* = 6.7 Hz, 2H), 2.81 (t, *J* = 6.1 Hz, 2H), 2.53 – 2.41 (m, 10H), 1.94 – 1.85 (m, 2H), 1.68 – 1.58 (m, 8H), 1.49 – 1.43 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 193.2, 146.6, 145.8, 139.0, 133.8, 133.3, 130.6, 127.5, 126.7, 125.0, 124.2, 113.0, 109.3, 66.6, 58.0, 57.4, 54.9, 42.4, 26.4, 25.9, 24.3. LCMS *m/z* calc for [M+H]⁺: 450.3, found: 450.1.

3'-(2-(piperidin-1-yl)ethoxy)-4'-((3-(piperidin-1-yl)propyl)amino)-[1,1'-biphenyl]-3-carbaldehyde (**16**)

Brown oil (600 mg, 1.33 mmol, 96%). ¹H NMR (300 MHz, CDCl₃): δ 10.07 (s, 1H), 8.05 (t, *J* = 1.6 Hz, 1H), 7.81 (m, 1H), 7.75 (dt, *J* = 7.7 Hz, *J* = 1.6 Hz, 1H), 7.55 (t, *J* = 7.7 Hz, 1H), 7.18 (dd, *J* = 8.2 Hz, *J* = 2.0 Hz, 1H), 7.07 (d, *J* = 2.0 Hz, 1H), 6.68 (d, *J* = 8.2 Hz, 1H), 4.95 (br s, 1H), 4.22 (t, *J* = 6.2 Hz, 2H), 3.24 (t, *J* = 6.7 Hz, 2H), 2.83 (t, *J* = 6.2 Hz, 2H), 2.56 – 2.41 (m, 10H), 1.91 – 1.87 (m, 2H); 1.67 – 1.59 (m, 8H), 1.49 – 1.45 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 192.7, 146.4, 142.5, 139.1, 136.8, 132.2, 129.3, 127.3, 120.4, 110.0, 66.6, 58.1, 57.4, 55.1, 54.7, 42.4, 26.4, 26.0, 24.3. LCMS *m/z* calc for [M+H]⁺: 450.3, found: 450.3.

3'-(2-(piperidin-1-yl)ethoxy)-4'-((3-(piperidin-1-yl)propyl)amino)-[1,1'-biphenyl]-4-carbaldehyde (**17**)

Brown oil (285 mg, 0.63 mmol, 88%). ¹H NMR (300 MHz, CDCl₃): δ 10.01 (s, 1H), 7.89 (d, *J* = 8.4 Hz, 2H), 7.69 (d, *J* = 8.4 Hz, 2H), 7.23 (dd, *J* = 8.4 Hz, *J* = 2.1, 1H), 7.10 (d, *J* = 2.1 Hz, 1H), 6.67 (d, *J* = 8.4 Hz, 1H), 5.05 (br s, 1H), 4.23 (t, *J* = 6.3 Hz, 2H), 3.27 (t, *J* = 6.6 Hz, 2H), 2.86 (t, *J* = 6.0 Hz, 2H), 2.61 – 2.39 (m, 10H), 1.93 (m, 2H), 1.75 – 1.58 (m, 8H), 1.53 – 1.43 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 191.9, 147.6, 146.2, 139.6, 134.0, 133.3, 127.0, 126.4,

121.1, 110.0, 66.5, 57.9, 57.2, 54.8, 42.1, 25.8, 25.5, 24.1. LCMS m/z calc for $[M+H]^+$: 450.3, found: 450.2.

3'-(2-(piperidin-1-yl)ethoxy)-4'-((2-(piperidin-1-yl)ethyl)amino)-[1,1'-biphenyl]-2-carbaldehyde (**18**)

Brown oil (459 mg, 1.05 mmol, 92%). ^1H NMR (300 MHz, CDCl_3): δ 10.03 (s, 1H), 7.98 (dd, $J = 7.8, 1.4$ Hz, 1H), 7.59 (tt, $J = 13.1, 6.5$ Hz, 1H), 7.45 – 7.41 (m, 2H), 6.87 (dd, $J = 8.0, 1.9$ Hz, 1H), 6.81 (d, $J = 1.9$ Hz, 1H), 6.66 (d, $J = 8.0$ Hz, 1H), 5.13 (s, 1H), 4.16 (t, $J = 5.8$ Hz, 2H), 3.25 (m, 2H), 2.85 (t, $J = 5.8$ Hz, 2H), 2.66 (t, $J = 6.3$ Hz, 2H), 2.59 – 2.50 (m, 4H), 2.49 – 2.40 (m, 4H), 1.67 – 1.39 (m, 12H). ^{13}C NMR (75 MHz, CDCl_3): δ 193.2, 146.7, 146.1, 139, 133.8, 133.3, 130.6, 127.5, 126.7, 125.2, 124.1, 109.4, 66.6, 58.1, 57.4, 55, 54.4, 40.2, 26.1, 26, 24.5, 24.2. LCMS m/z calc for $[M+H]^+$: 436.3, found 436.3.

4'-((2-(piperidin-1-yl)ethyl)amino)-3'-(3-(piperidin-1-yl)propoxy)-[1,1'-biphenyl]-2-carbaldehyde (**19**)

Brown oil (378 mg, 0.84 mmol, 92%). Brown oil (378 mg, 92%). ^1H NMR (300 MHz, CDCl_3): δ 10.04 (s, 1H), 7.98 (dd, $J = 7.8, 1.3$ Hz, 1H), 7.65 – 7.54 (m, 1H), 7.50 – 7.37 (m, 2H), 6.86 (dd, $J = 8.0, 1.8$ Hz, 1H), 6.80 (d, $J = 1.8$ Hz, 1H), 6.66 (d, $J = 8.0$ Hz, 1H), 5.02 (t, $J = 4.9$ Hz, 1H), 4.07 (t, $J = 6.2$ Hz, 2H), 3.25 (dd, $J = 11.5, 6.0$ Hz, 2H), 2.66 (t, $J = 6.2$ Hz, 2H), 2.57 – 2.32 (m, 10H), 1.67 – 1.54 (m, 8H), 1.52 – 1.41 (m, 4H). ^{13}C NMR (75 MHz, CDCl_3): δ 193.3, 146.7, 146.2, 138.8, 133.8, 133.3, 130.7, 127.5, 126.7, 125.2, 123.8, 112.2, 109.3, 66, 57.3, 56.2, 54.7, 54.4, 40.2, 26, 26.2, 25.9, 24.5, 24.4. LCMS m/z calc for $[M+H]^+$: 450.6, found 450.38

3'-(4-(piperidin-1-yl)butoxy)-4'-((2-(piperidin-1-yl)ethyl)amino)-[1,1'-biphenyl]-2-carbaldehyde (**20**)

Brown oil (150 mg, 0.32 mmol, 71%). ^1H NMR (300 MHz, CDCl_3): δ 10.04 (s, 1H), 7.98 (dd, $J = 7.8, 1.3$ Hz, 1H), 7.65 – 7.56 (m, 1H), 7.49 – 7.38 (m, 2H), 6.86 (dd, $J = 8.0, 1.8$ Hz, 1H), 6.78 (d, $J = 1.8$ Hz, 1H), 6.66 (d, $J = 8.0$ Hz, 1H), 5.01 (d, $J = 4.8$ Hz, 1H), 4.04 (t, $J = 6.2$ Hz, 2H), 3.31 – 3.18 (m, $J = 11.6, 4.6$ Hz, 2H), 2.66 (t, $J = 6.2$ Hz, 2H), 2.54 – 2.24 (m, 10H), 1.94 – 1.79 (m, 4H), 1.79 – 1.53 (m, 8H), 1.53 – 1.37 (m, 4H). ^{13}C NMR (75 MHz, CDCl_3): δ 193.3, 146.8, 146.2, 138.8, 133.8, 133.3, 130.7, 127.5, 126.7, 125.2, 123.7, 112.2, 109.4, 68.2, 59.1, 57.3, 54.6, 54.4, 40.3, 26.2, 25.9, 24.5, 23.5. LCMS m/z calc for $[M+H]^+$: 464.3, found 464.4.

3'-(3-(piperidin-1-yl)propoxy)-4'-((3-(piperidin-1-yl)propyl)amino)-[1,1'-biphenyl]-2-carbaldehyde (**21**)

Brown oil (573 mg, 1.24 mmol, 80%). ¹H NMR (300 MHz, CDCl₃): δ 10.02 (s, 1H), 7.98 (d, *J* = 7.6 Hz, 1H), 7.59 (t, *J* = 7.6 Hz, 1H), 7.49 – 7.36 (m, 2H), 6.85 (dd, *J* = 8.0, 1.7 Hz, 1H), 6.80 (s, 1H), 6.67 (d, *J* = 8.0 Hz, 1H), 4.79 (s, 1H), 4.07 (t, *J* = 6.4 Hz, 2H), 3.25 (d, *J* = 6.2 Hz, 2H), 2.58 – 2.33 (m, 12H), 2.07 – 1.99 (m, 2H), 1.96 – 1.79 (m, 2H), 1.61 (m, 8H), 1.51 – 1.41 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 193.3, 146.8, 145.9, 138.7, 133.8, 133.3, 130.7, 127.5, 125.1, 123.8, 112.3, 109.2, 67.0, 57.4, 56.0, 54.8, 54.7, 42.4, 26.9, 26.5, 25.9, 24.5. LCMS *m/z* calc for [M+H]⁺: 464.3, found 464.4.

4'-((4-(piperidin-1-yl)butyl)amino)-3'-(2-(piperidin-1-yl)ethoxy)-[1,1'-biphenyl]-2-carbaldehyde (**22**)

Brown oil (439 mg, 0.94 mmol, 97%). ¹H NMR (300 MHz, CDCl₃): δ 10.02 (s, 1H), 7.98 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.59 (td, *J* = 7.5, 1.5 Hz, 1H), 7.45 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.40 (d, *J* = 7.5 Hz, 1H), 6.86 (dd, *J* = 8.0, 1.9 Hz, 1H), 6.82 (d, *J* = 1.9 Hz, 1H), 6.66 (d, *J* = 8.0 Hz, 1H), 4.61 (s, 1H), 4.14 (t, *J* = 5.9 Hz, 2H), 3.21 (d, *J* = 6.1 Hz, 2H), 2.80 (t, *J* = 6.0 Hz, 2H), 2.63 – 2.26 (m, 10H), 1.77 – 1.38 (m, 16H). ¹³C NMR (75 MHz, CDCl₃): δ 193.2, 146.6, 145.7, 139.0, 133.8, 133.3, 130.6, 127.5, 126.7, 125.0, 124.2, 113.1, 109.2, 66.6, 59.1, 58.0, 55.0, 54.6, 43.4, 27.5, 26.0, 24.6, 24.5, 24.2. LCMS *m/z* calc for [M+H]⁺: 464.65, found 464.45

3'-(2-cyclohexylethoxy)-4'-((3-(piperidin-1-yl)propyl)amino)-[1,1'-biphenyl]-3-carbaldehyde (**23**)

Brown oil (748 mg, 1.67 mmol, 80%). ¹H NMR (300 MHz, CDCl₃): δ 10.03 (s, 1H), 7.99 (d, *J* = 7.4 Hz, 1H), 7.60 – 7.57 (m, 1H), 7.48 – 7.41 (m, 2H), 6.86 – 6.66 (m, 3H), 4.77 (br s, 1H), 4.06 (t, *J* = 6.8 Hz, 2H), 3.26 (m, 2H), 2.48 (m, 6H), 2.46 – 0.97 (m, 21H). ¹³C NMR (75 MHz, CDCl₃): δ 193.3, 146.8, 146.0, 138.6, 133.8, 133.3, 130.6, 127.5, 126.6, 125.2, 123.6, 112.0, 109.1, 66.5, 57.4, 54.7, 42.4, 36.7, 34.8, 33.3, 26.4, 26.2, 25.7, 24.3. LCMS *m/z* calc for [M+H]⁺: 449.3, found 449.4.

General procedure for the synthesis of compounds 24-30 is exemplified by the protocol used for the synthesis of 24. 3'-(2-(piperidin-1-yl)ethoxy)-4'-((3-(piperidin-1-yl)propyl)amino)-[1,1'-biphenyl]-4-carbaldehyde **17** (290 mg, 0.65 mmol) was dissolved in DCE (12 mL). Piperidine (96 μL, 0.97 mmol) was added. After 2 h at rt, NaBH(OAc)₃ (206 mg, 0.97 mmol) and acetic acid (56 μL, 0.97 mmol) were added. After 16 h at rt, saturated

NaHCO₃ solution was added. The reaction mixture was stirred for another hour. DCM was added and the layers were separated. The organic layer was washed three times with saturated NaHCO₃ solution. The organic layer was dried over MgSO₄ and evaporated. The residue was purified by flash chromatography (DCM/MeOH(NH₃), 10:0 to 9:1 (v/v)) to afford 2-[2-(Piperidin-1-yl)ethoxy]-*N*-[3-(piperidin-1-yl)propyl]-4-[4-(piperidin-1-ylmethyl)phenyl]aniline **24** as a colorless oil (260 mg, 0.50 mmol, 77%). ¹H NMR (300 MHz, CDCl₃): δ 7.51 (d, *J* = 8.5 Hz, 2H), 7.32 (d, *J* = 8.5 Hz, 2H), 7.13 (dd, *J* = 8.1 Hz, *J* = 1.9 Hz, 1H), 7.04 (d, *J* = 1.9 Hz, 1H), 6.66 (d, *J* = 8.2 Hz, 1H), 4.20 (t, *J* = 6.0 Hz, 2H), 3.50 (s, 2H), 3.22 (t, *J* = 6.7 Hz, 2H), 2.81 (t, *J* = 6.0 Hz, 2H), 2.54 – 2.34 (m, 14H), 1.93 – 1.84 (m, 2H), 1.66 – 1.38 (m, 18H). ¹³C NMR (75 MHz, CDCl₃): δ 146.2, 140.2, 138.3, 136.1, 129.6, 129.1, 126.0, 120.2, 110.1, 66.6, 63.6, 58.1, 57.5, 55.1, 54.5, 42.5, 26.6, 26.0, 24.4. LCMS *m/z* calc for [M+H]⁺: 519.4, found: 519.3. HR-MS: *m/z* Calculated: 519.4057, found: 519.4060 [M+H]⁺ = C₃₃H₅₁N₄O.

4-(4-[(Dimethylamino)methyl]phenyl)-2-[2-(piperidin-1-yl)ethoxy]-*N*-[3-(piperidin-1-yl)propyl] aniline (**25**)

In the present case dimethylamine 2 M in THF was used and the product was obtained as a colorless oil (130 mg, 0.27 mmol, 61%). ¹H NMR (300 MHz, CDCl₃): δ 7.49 (d, *J* = 8.4 Hz, 2H), 7.31 (d, *J* = 8.4 Hz, 2H), 7.12 (dd, *J* = 8.2 Hz, *J* = 2.1 Hz, 1H), 7.04 (d, *J* = 2.1 Hz, 1H), 6.65 (d, *J* = 8.2 Hz, 1H), 4.20 (t, *J* = 6.1 Hz, 2H), 3.45 (s, 2H), 3.23 (t, *J* = 6.8 Hz, 2H), 2.82 (t, *J* = 6.1 Hz, 2H), 2.55 – 2.41 (m, 10H), 2.25 (s, 3H), 1.90 – 1.85 (m, 2H), 1.66 – 1.58 (m, 8H), 1.51 – 1.44 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 146.2, 140.4, 138.3, 136.4, 129.5, 129.0, 126.4, 120.2, 110.0, 66.4, 64.1, 58.1, 57.4, 54.8, 45.3, 42.5, 26.4, 25.8, 24.3. LCMS *m/z* calc for [M+H]⁺: 479.3, found: 479.4. HR-MS: *m/z* Calculated: 479.3744, found: 479.3716 [M+H]⁺ = C₃₀H₄₇N₄O.

2-[2-(1-piperidyl)ethoxy]-4-[3-(1-piperidylmethyl)phenyl]-*N*-[3-(1-piperidyl)propyl]aniline (**26**)

Brown oil (17 mg, 0.03 mmol, 5%). ¹H NMR (300 MHz, CDCl₃): δ 7.49 – 7.47 (m, 1H), 7.45 – 7.43 (m, 1H), 7.33 (t, *J* = 7.5 Hz, 1H), 7.24 – 7.20 (m, 1H), 7.5 (dd, *J* = 8.1 Hz, *J* = 1.8 Hz, 1H), 7.06 (d, *J* = 1.8 Hz, 1H), 6.66 (d, *J* = 8.1 Hz, 1H), 4.22 (t, *J* = 6.0 Hz, 2H), 3.54 (s, 2H), 3.23 (t, *J* = 6.9 Hz, 2H), 2.83 (t, *J* = 6.7 Hz, 2H), 2.6 – 2.4 (m, 14H); 1.89 (quint, *J* = 6.7 Hz, 2H), 1.70 – 1.50 (m, 12H), 1.50 – 1.40 (m, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 146.2, 141.4, 138.4, 129.2, 128.4, 127.3, 127.0, 125.0, 120.3, 110.3, 110.0, 66.6, 64.0, 58.1, 57.4, 55.1, 54.7,

54.5, 42.5, 26.5, 26.0, 25.9, 24.4, 24.2. LCMS m/z calc for $[M+H]^+$: 519.4, Found: 519.3. HR-MS: m/z Calculated: 519.3985, found: 519.4060 $[M+H]^+ = C_{33}H_{51}N_4O$.

2-[2-(Piperidin-1-yl)ethoxy]-*N*-[3-(piperidin-1-yl)propyl]-4-[2-(piperidin-1-ylmethyl)phenyl]aniline (**27**)

Colorless oil (114 mg, 0.22 mmol, 66%). 1H NMR (300 MHz, $CDCl_3$): δ 7.54 – 7.51 (m, 1H), 7.29 – 7.25 (m, 3H), 6.93 (d, $J = 1.8$ Hz, 1H), 6.89 (dd, $J = 8.0$ Hz, $J = 1.8$ Hz, 1H), 6.64 (d, $J = 8.0$ Hz, 1H), 4.98 (br s, 1H), 4.15 (t, $J = 6.1$ Hz, 2H), 3.42 (s, 2H), 3.23 (t, $J = 6.8$ Hz, 2H), 2.80 (t, $J = 6.1$ Hz, 2H), 2.52 – 2.30 (m, 14H), 1.90 (quint, $J = 6.7$ Hz, 2H), 1.68 – 1.38 (m, 18H). ^{13}C NMR (75 MHz, $CDCl_3$): δ 145.3, 143.1, 137.1, 136.1, 130.1, 129.5, 126.3, 122.8, 113.0, 109.3, 66.4, 60.8, 58.1, 57.4, 54.9, 54.4, 42.6, 26.6, 26.0, 24.3. LCMS m/z calc for $[M+H]^+$: 519.4, found: 519.2. HR-MS: m/z Calculated: 519.4057, found: 519.4056 $[M+H]^+ = C_{33}H_{51}N_4O$.

4-[2-(Morpholin-4-ylmethyl)phenyl]-2-[2-(piperidin-1-yl)ethoxy]-*N*-[3-(piperidin-1-yl)propyl]aniline (**28**)

Colorless oil (126 mg, 0.24 mmol, 40%). 1H NMR (300 MHz, $CDCl_3$): δ 7.53 – 7.48 (m, 1H); 7.29 – 7.26 (m, 3H), 6.94 – 6.89 (m, 2H), 6.64 (d, $J = 8.6$ Hz, 1H), 4.80 (br s, 1H), 4.14 (t, $J = 6.0$ Hz, 2H), 3.68 (t, $J = 4.4$ Hz, 4H); 3.45 (s, 2H); 3.23 (t, $J = 6.8$ Hz, 2H); 2.79 (t, $J = 6.0$ Hz, 2H); 2.52 – 2.38 (m, 14H), 1.90 (quint, $J = 6.8$ Hz, 2H), 1.66 – 1.56 (m, 8H), 1.50 – 1.42 (m, 4H). ^{13}C NMR (75 MHz, $CDCl_3$): δ 145.4, 143.3, 137.8, 135.1, 130.3, 129.2, 126.5, 122.8, 112.9, 109.3, 67.2, 66.3, 60.5, 58.1, 57.5, 54.9, 53.4, 42.6, 26.6, 26.0, 24.3. LCMS m/z calc for $[M+H]^+$: 521.4, Found: 521.4. HR-MS: m/z Calculated: 521.3850, found: 521.3852 $[M+H]^+ = C_{32}H_{49}N_4O_2$.

4-(2-[(4-Methylpiperazin-1-yl)methyl]phenyl)-2-[2-(piperidin-1-yl)ethoxy]-*N*-[3-(piperidin-1-yl)propyl]aniline (**29**)

Colorless oil (213 mg, 0.40 mmol, 54%). 1H NMR (300 MHz, $CDCl_3$): δ 7.48 – 7.45 (m, 1H), 7.27 – 7.24 (m, 3H), 6.94 – 6.90 (m, 2H), 6.63 (d, $J = 8.0$ Hz, 1H), 4.13 (t, $J = 6.1$ Hz, 2H), 3.44 (s, 2H), 3.22 (t, $J = 6.8$ Hz, 2H), 2.79 (t, $J = 6.1$ Hz, 2H), 2.50 – 2.27 (m, 21H), 1.88 (quint, $J = 7.5$ Hz, 2H), 1.66 – 1.56 (m, 8H), 1.48 – 1.42 (m, 4H). ^{13}C NMR (75 MHz, $CDCl_3$): δ 145.3, 143.3, 137.8, 135.5, 130.3, 129.3, 126.4, 122.8, 113.0, 109.2, 66.5, 60.1, 58.1, 57.5, 55.0, 46.1, 42.6, 26.7, 26.0, 24.3. LCMS m/z calc for $[M+H]^+$: 534.2, found: 534.4. HR-MS: m/z Calculated: 534.4166, found: 534.4170 $[M+H]^+ = C_{33}H_{52}N_5O$.

4-(2-[(Dimethylamino)methyl]phenyl)-2-[2-(piperidin-1-yl)ethoxy]-*N*-[3-(piperidin-1-yl)propyl] aniline (**30**)

In the present case 13 equiv. of dimethylamine 2M in THF was used. Compound was obtained as a colorless oil (162 mg, 0.34 mmol, 51%). ¹H NMR (300 MHz, CDCl₃): δ 7.51 – 7.49 (m, 1H), 7.30 – 7.25 (m, 3H), 6.91 (d, *J* = 1.8 Hz, 1H), 6.85 (dd, *J* = 8.0 Hz, *J* = 1.8 Hz, 1H), 6.65 (d, *J* = 8.0 Hz, 1H), 4.74 (br s, 1H), 4.14 (t, *J* = 6.2 Hz, 2H), 3.39 (s, 2H), 3.23 (t, *J* = 6.7 Hz, 2H), 2.80 (t, *J* = 6.2 Hz, 2H), 2.54 – 2.40 (m, 10H), 2.18 (s, 6H), 1.93 – 1.84 (m, 2H), 1.67 – 1.57 (m, 8H), 1.50 – 1.42 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 145.4, 142.9, 137.7, 136.3, 130.0, 129.4, 126.5, 122.7, 112.9, 109.3, 66.3, 61.1, 58.1, 57.5, 54.9, 45.4, 42.6, 26.6, 26.0, 24.3. LCMS *m/z* calc for [M+H]⁺: 479.3, Found: 479.3. HR-MS: *m/z* Calculated: 479.3744, found: 479.3741 [M+H]⁺ = C₃₀H₄₇ N₄O.

General procedure for the synthesis of compounds 31-36 is exemplified by the protocol used for the synthesis of 31. To a solution of 3'-(2-cyclohexylethoxy)-4'-((3-(piperidin-1-yl)propyl)amino)-[1,1'-biphenyl]-3-carbaldehyde **23** (300 mg, 0.67 mmol) and dimethylamine hydrochloride (110 mg, 1.34 mmol) in EtOH (2 mL) was added triethylamine (186 μL, 1.34 mmol) and titanium isopropoxide (400 μL, 1.34 mmol). The mixture was stirred for 12 h at rt. NaBH₄ (51 mg, 1.34 mmol) was then added and the mixture was further stirred for 2 hours. The reaction was quenched by pouring the mixture into aqueous ammonia (2.5 mL) and extracted with DCM (3 x 10 mL). The combined organic layers were dried over MgSO₄ and evaporated. The residue was purified by flash chromatography (DCM/MeOH(NH₃), 10:0 to 9:1 (v/v)) to afford 3-(2-cyclohexylethoxy)-2'-((dimethylamino)methyl)-*N*-(3-(piperidin-1-yl)propyl)-[1,1'-biphenyl]-4-amine as a colorless oil (157 mg, 0.33 mmol, 49%). ¹H NMR (300 MHz, CDCl₃): δ 7.53 – 7.49 (m, 1H), 7.33 – 7.28 (m, 3H), 6.91 (d, *J* = 1.8 Hz, 1H), 6.85 (dd, *J* = 8.0 Hz, *J* = 1.8 Hz, 1H), 6.65 (d, *J* = 8.0 Hz, 1H), 4.64 (br s, 1H), 4.05 (t, *J* = 6.8 Hz, 2H), 3.40 (s, 2H), 3.24 (t, *J* = 6.4 Hz, 2H), 2.49 – 2.40 (m, 6H), 2.18 (s, 6H), 1.94 – 1.85 (m, 2H), 1.80 – 1.60 (m, 11H), 1.54 – 1.42 (m, 3H), 1.33 – 1.10 (m, 3H), 1.06 – 0.92 (m, 2H). ¹³C NMR (75 MHz, CDCl₃): δ 145.6, 143.0, 137.4, 136.3, 130.2, 129.9, 129.5, 126.6, 126.4, 122.2, 112.2, 109.1, 66.3, 61.1, 57.6, 54.8, 45.4, 42.7, 36.8, 34.8, 33.4, 26.6, 26.5, 26.2, 25.9, 24.4. LCMS *m/z* calc for [M+H]⁺: 478.4, Found: 478.3. HR-MS: *m/z* Calculated: 478.3719, found: 478.3799, [M+H]⁺ = C₃₀H₄₈ N₃O.

2'-((Dimethylamino)methyl)-3-(3-(piperidin-1-yl)propoxy)-*N*-(3-(piperidin-1-yl)propyl)-[1,1'-biphenyl]-4-amine (**32**)

Brown oil (75 mg, 0.15 mmol, 47%). ¹H NMR (300 MHz, CDCl₃): δ 7.54 – 7.47 (m, 1H), 7.35 – 7.24 (m, 3H), 6.91 (d, *J* = 1.8 Hz, 1H), 6.85 (dd, *J* = 8.1, 1.8 Hz, 1H), 6.64 (d, *J* = 8.1 Hz, 1H), 4.58 (s, 1H), 4.05 (t, *J* = 6.5 Hz, 2H), 3.39 (s, 2H), 3.23 (t, *J* = 6.7 Hz, 2H), 2.59 – 2.34 (m, 12H), 2.19 (s, 6H), 2.09 – 1.97 (m, 2H), 1.95 – 1.82 (m, 2H), 1.69 – 1.53 (m, 8H), 1.51 – 1.39 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 145.5, 143.0, 137.4, 136.4, 130.2, 129.9, 129.6, 126.6, 126.4, 122.4, 112.4, 109.2, 66.9, 61.1, 57.6, 56.2, 54.8, 54.7, 45.4, 42.6, 27.0, 26.7, 26.0, 24.5. LCMS *m/z* calc for [M+H]⁺: 493.4, found: 493.4. HR-MS: *m/z* Calculated: 493.3901, found: 493.3906 [M+H]⁺ = C₃₁H₄₉N₄O.

2'-((Dimethylamino)methyl)-3-(2-(piperidin-1-yl)ethoxy)-*N*-(2-(piperidin-1-yl)ethyl)-[1,1'-biphenyl]-4-amine (**33**)

Brown oil (25 mg, 0.05 mmol, 30%). ¹H NMR (300 MHz, CDCl₃): δ 7.51 (dd, *J* = 4.7, 2.3 Hz, 1H), 7.33 – 7.24 (m, 3H), 6.91 (d, *J* = 1.8 Hz, 1H), 6.87 (dd, *J* = 8.0, 1.8 Hz, 1H), 6.63 (d, *J* = 8.0 Hz, 1H), 4.96 (s, 1H), 4.15 (t, *J* = 5.8 Hz, 2H), 3.40 (s, 2H), 3.25 (t, *J* = 6.1 Hz, 2H), 2.84 (t, *J* = 5.8 Hz, 2H), 2.73 – 2.39 (m, 10H), 2.19 (s, 6H), 1.66 – 1.56 (m, 8H), 1.46 (d, *J* = 5.1 Hz, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 145.59, 142.95, 137.63, 136.40, 130.17, 129.91, 129.49, 126.59, 126.47, 122.65, 112.71, 109.33, 77.45, 77.03, 76.60, 66.41, 61.11, 58.21, 57.65, 54.93, 54.46, 45.39, 40.37, 26.14, 26.03, 24.50, 24.21. LCMS *m/z* calc for [M+H]⁺: 465.3, found 465.4. HR-MS: *m/z* Calculated: 493.39010, found: 493.3906 [M+H]⁺ = C₃₁H₄₉N₄O.

2'-((Dimethylamino)methyl)-*N*-(2-(piperidin-1-yl)ethyl)-3-(3-(piperidin-1-yl)propoxy)-[1,1'-biphenyl]-4-amine (**34**)

Brown oil (36 mg, 0.07 mmol, 30%). ¹H NMR (300 MHz, CDCl₃): δ 7.58 – 7.43 (m, 1H), 7.37 – 7.24 (m, 3H), 6.92 (d, *J* = 1.8 Hz, 1H), 6.86 (dd, *J* = 8.0, 1.8 Hz, 1H), 6.63 (d, *J* = 8.0 Hz, 1H), 4.86 (s, 1H), 4.05 (t, *J* = 6.2 Hz, 2H), 3.40 (s, 2H), 3.33 – 3.16 (m, 2H), 2.66 (t, *J* = 6.3 Hz, 2H), 2.59 – 2.32 (m, 10H), 2.19 (s, 6H), 2.10 – 1.97 (m, 2H), 1.70 – 1.53 (m, 8H), 1.53 – 1.40 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 145.7, 143.0, 137.5, 136.4, 130.2, 129.9, 129.6, 126.6, 126.5, 122.4, 112.3, 109.3, 66.8, 61.2, 57.6, 56.3, 54.7, 54.5, 45.4, 40.4, 27.1, 26.2, 26.0, 24.5. LCMS *m/z* calc for [M+H]⁺: 479.4, found: 479.4. HR-MS: *m/z* Calculated: 479.3744, found: 479.3742 [M+H]⁺ = C₃₀H₄₇N₄O.

2'-((Dimethylamino)methyl)-3-(4-(piperidin-1-yl)butoxy)-*N*-(2-(piperidin-1-yl)ethyl)-[1,1'-biphenyl]-4-amine (**35**)

Brown oil (35 mg, 0.07 mmol, 28%). ¹H NMR (300 MHz, CDCl₃): δ 7.61 – 7.41 (m, 1H), 7.40 – 7.19 (m, 3H), 6.90 (d, *J* = 1.6 Hz, 1H), 6.86 (dd, *J* = 8.0, 1.6 Hz, 1H), 6.63 (d, *J* = 8.0 Hz, 1H), 4.86 (s, 1H), 4.16 – 3.91 (m, 2H), 3.36 (s, 2H), 3.32 – 3.16 (m, 2H), 2.66 (t, *J* = 6.3 Hz, 2H), 2.39 (dd, *J* = 19.5, 12.2 Hz, 10H), 2.19 (s, 6H), 1.96 – 1.33 (m, 16H). ¹³C NMR (75 MHz, CDCl₃): δ 145.7, 143.0, 137.5, 136.4, 130.2, 129.9, 129.5, 126.6, 126.4, 122.3, 112.3, 109.3, 68.0, 61.2, 59.2, 57.6, 54.6, 54.5, 45.4, 40.5, 27.7, 26.2, 26.0, 24.5, 24.5, 23.6. LCMS *m/z* calc for [M+H]⁺: 493.4, found 493.5. HR-MS: *m/z* Calculated: 493.3901, found: 493.3906 [M+H]⁺ = C₃₁H₄₉N₄O.

2'-((Dimethylamino)methyl)-*N*-(4-(piperidin-1-yl)butyl)-3-(2-(piperidin-1-yl)ethoxy)-[1,1'-biphenyl]-4-amine (**36**)

Brown oil (75 mg, 0.15 mmol, 47%). ¹H NMR (300 MHz, CDCl₃): δ 7.54 – 7.47 (m, 1H), 7.35 – 7.24 (m, 3H), 6.91 (d, *J* = 1.8 Hz, 1H), 6.85 (dd, *J* = 8.0, 1.8 Hz, 1H), 6.64 (d, *J* = 8.0 Hz, 1H), 4.58 (s, 1H), 4.05 (t, *J* = 6.5 Hz, 2H), 3.39 (s, 2H), 3.23 (t, *J* = 6.7 Hz, 2H), 2.59 – 2.34 (m, 12H), 2.19 (s, 6H), 2.09 – 1.97 (m, 2H), 1.95 – 1.82 (m, 2H), 1.69 – 1.53 (m, 8H), 1.51 – 1.39 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 145.5, 143.0, 137.4, 136.4, 130.2, 129.9, 129.6, 126.6, 126.4, 122.4, 112.4, 109.2, 66.9, 61.1, 57.6, 56.2, 54.8, 54.7, 45.4, 42.6, 27.0, 26.7, 26.0, 24.5. LCMS *m/z* calc for [M+H]⁺: 493.4, found: 493.4. HR-MS: *m/z* Calculated: 493.3901, found: 493.3906 [M+H]⁺ = C₃₁H₄₉N₄O.

3-(2-(Piperidin-1-yl)ethoxy)-*N*-(3-(piperidin-1-yl)propyl)-[1,1'-biphenyl]-4-amine (**37**)

To a solution of benzeneboronic acid (108 mg, 0.88 mmol) in a mixture of toluene (8 mL) and EtOH (3 mL), K₂CO₃ (132 mg, 0.96 mmol) and **11** (156 mg, 0.37 mmol) were added. The reaction was stirred for 30 min and deoxygenated by passing a stream of N₂ through it. Pd₂dba₃ (6.73 mg, 0.007 mmol) and P(*o*-tol)₃ (22 mg, 0.073 mmol) were added and the mixture was refluxed overnight. After cooling, the mixture was poured into 1N NaOH and extracted three times with dichloromethane. The combined organic layers were dried over MgSO₄ and evaporated. The residue was purified by flash chromatography (DCM/MeOH(NH₃), 10:0 to 95:5 (v/v)) to afford a brown oil (110 mg, 0.26 mmol, 71 %). ¹H NMR (300 MHz, CD₂Cl₂): δ 7.61 – 7.53 (m, 2H), 7.44 – 7.36 (m, 2H), 7.30 – 7.22 (m, 1H), 7.15 (dd, *J* = 8.2, 2.0 Hz, 1H), 7.09 (d, *J* = 2.0 Hz, 1H), 6.68 (d, *J* = 8.2 Hz, 1H), 4.94 (s, 1H), 4.18 (t, *J* = 6.0 Hz, 2H), 3.24 (t, *J* = 6.7 Hz, 2H), 2.78 (t, *J* = 6.0 Hz, 2H), 2.60 – 2.31 (m, 10H), 1.91 – 1.75 (m, 2H), 1.70 – 1.55

(m, 8H), 1.55 – 1.38 (m, 4H). ^{13}C NMR (75 MHz, CD_2Cl_2): δ 148.3, 143.4, 140.7, 130.5, 128.0, 127.8, 122.0, 112.2, 111.6, 68.6, 60.0, 59.1, 56.9, 56.6, 44.2, 28.2, 28, 27.8, 26.3, 26.2. LCMS m/z calc 422.3 for $[\text{M}+\text{H}]^+$: 422.3, found: . HR-MS: m/z Calculated: 422.3093, found: 422.3156 $[\text{M}+\text{H}]^+ = \text{C}_{27}\text{H}_{40}\text{N}_3\text{O}$.

1-(2-(3-Bromophenoxy)ethyl)piperidine (**38**)

3-Bromophenol (1.63 g, 9.42 mmol) was suspended in ACN (50 mL) and K_2CO_3 (3.91 g, 28.3 mmol) was added. The reaction mixture was stirred at 80 °C for 30 min. Then 1-(2-Chloroethyl)piperidine hydrochloride (2.43 g, 13.2 mmol) was added. The reaction mixture was stirred at 80 °C for 12 h. The inorganics were removed by filtration and the solvent was evaporated. The residue was dissolved in DCM (50 mL) and washed twice with a 1N NaOH solution. The organic layers were combined and dried over MgSO_4 , filtrated and concentrated in vacuo to afford **38** (2.45 g, 8.57 mmol, 91%). The product was used without further purification in the next step. ^1H NMR (300 MHz, CDCl_3): δ 7.14 (d, $J = 8.1$ Hz, 1H), 7.08 – 7.04 (m, 2H), 6.83 (ddd, $J = 8.1, 2.5, 1.4$ Hz, 1H), 4.08 (t, $J = 6.1$ Hz, 2H), 2.75 (t, $J = 6.1$, 2H), 1.65 – 1.53 (m, 6H), 1.49 – 1.39 (m, 2H). LCMS m/z calc for $[\text{M}+\text{H}]^+$: 286.1, 288.1 found: 286.0, 288.0

N-(2-(piperidin-1-yl)ethyl)-[1,1'-biphenyl]-4-amine (**39**)

3-Phenylphenol (1.02 g, 6.02 mmol) was suspended in ACN (50 mL) and K_2CO_3 (2.49 g, 18.0 mmol) was added. The reaction mixture was stirred at 80 °C for 30 min. Then 1-(2-Chloroethyl)piperidine hydrochloride (1.55 g, 8.42 mmol) was added. The reaction mixture was stirred at 80 °C for 12 h. The inorganics were removed by filtration and the solvent was evaporated. The residue was dissolved in DCM (50 mL) and washed twice with a 1N NaOH solution. The organic layers were combined and dried over MgSO_4 , filtrated and concentrated. The residue was purified by flash chromatography (Cyclohexane/AcOEt), 10:0 to 5:5 (v/v)) to afford a yellow oil (690 mg, 2.45 mmol, 41 %). ^1H NMR (300 MHz, CDCl_3): δ 7.64 – 7.56 (m, 2H), 7.44 (t, $J = 7.6$ Hz, 2H), 7.35 (t, $J = 7.6$ Hz, 2H), 7.22 – 7.14 (m, 2H), 6.91 (ddd, $J = 8.2, 2.5, 0.8$ Hz, 1H), 4.18 (t, $J = 6.1$ Hz, 2H), 2.82 (t, $J = 6.1$ Hz, 2H), 2.61 – 2.46 (m, 4H), 1.72 – 1.57 (m, 4H), 1.53 – 1.41 (m, 2H). ^{13}C NMR (75 MHz, CD_2Cl_2): δ 159.2, 142.7, 141.1, 129.7, 128.7, 127.4, 127.2, 119.7, 113.7, 113.3, 66.0, 58.0, 55.1, 26, 24.2. LCMS m/z calc for $[\text{M}+\text{H}]^+$: 282.2 found: 282.1. HR-MS: m/z Calculated: 282.1939, found: 282.1846 $[\text{M}+\text{H}]^+ = \text{C}_{19}\text{H}_{24}\text{NO}$.

3'-(2-(Piperidin-1-yl)ethoxy)-[1,1'-biphenyl]-2-carbaldehyde (**40**)

To a solution of 2-formylbenzeneboronic acid (893 mg, 5.95 mmol) in a mixture of toluene (113 mL) and EtOH (45 mL), K₂CO₃ (891 mg, 6.45 mmol) and **38** (1.4 g, 4.96 mmol) were added. The reaction was stirred for 30 min and deoxygenated by passing a stream of N₂ through it. Pd₂dba₃ (91 mg, 0.02 mmol) and P(*o*-tol)₃ (302 mg, 0.99 mmol) were added and the mixture was refluxed for 2 h. After cooling, the mixture was poured into 1N NaOH and extracted three times with dichloromethane. The combined organic layers were dried over MgSO₄ and evaporated to afford an orange oil which was used without further purification (1.27 g, 4.11 mmol, 83 %). ¹H NMR (300 MHz, CDCl₃): δ 10.00 (d, *J* = 0.8 Hz, 1H), 8.04 (d, *J* = 7.5 Hz, 1H), 7.63 (d, *J* = 7.5 Hz, 1H), 7.50 – 7.34 (m, 3H), 6.99 – 6.93 (m, 3H), 4.17 (t, *J* = 5.9 Hz, 2H), 2.83 (t, *J* = 5.9 Hz, 2H), 2.56 (m, 4H), 1.65 – 1.60 (m, 4H), 1.50 – 1.44 (m, 2H). LCMS *m/z* calc for [M+H]⁺: 310.1, found: 310.12.

N,N-Dimethyl-1-(3'-(2-(piperidin-1-yl)ethoxy)-[1,1'-biphenyl]-2-yl)methanamine (**41**)

To a solution of **40** (925 mg, 2.99 mmol) in DCE (37 mL), dimethylamine 2.0 M in THF (15 mL, 29.9 mmol), NaBH(OAc)₃ (950 mg, 4.48 mmol) and acetic acid (0.26 mL, 4.48 mmol) were added and the mixture was stirred at rt for 12 h. The reaction was quenched by pouring the mixture into saturated NaHCO₃ solution (25 mL) and extracted with DCM (3 x 50 mL). The combined organic layers were dried over MgSO₄ and evaporated. The residue was purified by flash chromatography (DCM/MeOH(NH₃), 10:0 to 97:3 (v/v)) to afford a brown oil (266 mg, 0.79 mmol, 26 %). ¹H NMR (300 MHz, MeOD): δ 7.51 (dd, *J* = 7.4, 1.6 Hz, 1H), 7.39 – 7.27 (m, 3H), 7.25 – 7.19 (m, 1H), 6.95 (m, 1H), 6.92 – 6.84 (m, 2H), 4.17 (t, *J* = 5.7 Hz, 2H), 3.45 (s, 2H), 2.80 (t, *J* = 5.7 Hz, 2H), 2.57 (d, *J* = 5.2 Hz, 4H), 2.10 (s, 6H), 1.64 (m, 4H), 1.50 (m, 2H). ¹³C NMR (75 MHz, CDCl₃): δ 158.4, 142.9, 142.2, 136.3, 129.8, 128.8, 127.3, 126.6, 122.1, 122.1, 115.9, 113.1, 66, 30.9, 58, 55.1, 45.4, 26, 24.2. LCMS *m/z* calc for [M+H]⁺: 339.2, found: 339.2. HR-MS: *m/z* Calculated: 339.2358, found: 339.2422 [M+H]⁺ = C₂₂H₃₁N₂O.

4-Bromo-*N*-(2-(piperidin-1-yl)ethyl)aniline (**42**)

To solution of 4-bromoaniline (1.34 mL, 12 mmol) in DMF (50 mL), K₂CO₃ (3.2 g, 23 mmol), NaI (8.7 g, 58 mmol) and 3-chloropropylpiperidine hydrochloride (3.4 g, 18 mmol) were added. The reaction mixture was stirred at 100 °C for 24 h. DMF was removed under reduced pressure and the residue was taken up in 20 mL of water. The aqueous layer was extracted with DCM (3 x 60 mL). The combined organic layers were dried over MgSO₄ and evaporated. The residue was purified by column chromatography (EtOAc/MeOH, 8.5:1.5 (v:v)) to afford a brown oil

(779 mg, 2.76 mmol, 23 %). ^1H NMR (300 MHz, CDCl_3): δ 7.23 (d, J = 8.8 Hz, 2H), 6.47 (d, J = 8.8 Hz, 1H), 3.15 (t, J = 6.2 Hz, 2H), 2.67 – 2.41 (m, 6H), 1.97 – 1.76 (m, 2H), 1.77 – 1.44 (m, 6H). ^{13}C NMR (75 MHz, CDCl_3): δ 147.7, 131.9, 114.1, 108.4, 57.7, 54.5, 43.4, 29.7, 25.5, 24. LCMS m/z calc for $[\text{M}+\text{H}]^+$: 283.1, 285.1 found: 283.1, 285.1

4'-((3-(piperidin-1-yl)propyl)amino)-[1,1'-biphenyl]-2-carbaldehyde (**43**)

To a solution of 2-formylbenzeneboronic acid (791 mg, 5.27 mmol) in a mixture of toluene (35 mL) and EtOH (17 mL), K_2CO_3 (724 mg, 5.24 mmol) and **42** (779 mg, 2.62 mmol) were added. The reaction was stirred for 30 min and deoxygenated by passing a stream of N_2 through it. Pd_2dba_3 (133 mg, 0.055 mmol) and $\text{P}(o\text{-tol})_3$ (395 mg, 0.48 mmol) were added and the mixture was refluxed for 96 h. After cooling, the mixture was poured into water and extracted with dichloromethane. The combined organic layers were dried over MgSO_4 and evaporated. The residue was purified by semi-preparative chromatography (eluent H_2O formic, ACN formic, 100:0 to 70:30 (v/v)) to afford orange oil (341 mg, 1.05 mmol, 40%). ^1H NMR (300 MHz, CDCl_3): δ 10.02 (d, J = 0.7 Hz, 1H), 8.57 (s, 1H), 7.98 (dd, J = 7.7, 1.0 Hz, 1H), 7.64 – 7.55 (m, 1H), 7.47 – 7.35 (m, 2H), 7.22 – 7.14 (m, 2H), 6.71 (d, J = 8.6 Hz, 2H), 3.34 – 3.23 (m, 2H), 3.11 – 2.99 (m, 6H), 2.13 (dd, J = 13.9, 6.5 Hz, 2H), 1.97 – 1.84 (m, 4H), 1.72 – 1.53 (m, 2H). ^{13}C NMR (75 MHz, CDCl_3): δ 193.2, 168.3, 148.2, 146.4, 133.6, 133.4, 131.3, 130.6, 127.5, 126.7, 126, 112.3, 55.1, 53.1, 40.9, 23.8, 23.1, 22.6. LCMS m/z calc for $[\text{M}+\text{H}]^+$: 323.2, found 323.2.

2'-((Dimethylamino)methyl)-*N*-(3-(piperidin-1-yl)propyl)-[1,1'-biphenyl]-4-amine (**44**)

To a solution of **43** (156 mg, 0.42 mmol) and dimethylamine hydrochloride (69 mg, 0.85 mmol) in EtOH (1 mL) was added triethylamine (0.12 mL, 0.85 mmol) and titanium isopropoxide (0.25 mL, 0.85 mmol). The mixture was stirred at rt for 12 h. NaBH_4 (32 mg, 0.85 mmol) was added and the resulting mixture was further stirred for 2 h. The reaction was quenched by pouring the mixture into aqueous ammonia (2.5 mL) and extracted with DCM (3 x 10 mL). The combined organic layers were dried over MgSO_4 and evaporated. The residue was purified by flash chromatography (DCM/MeOH(NH_3), 10:0 to 98:2 (v/v)) to afford brown oil (119 mg, 0.34 mmol, 40%). ^1H NMR (300 MHz, CDCl_3): δ 7.60 – 7.45 (m, 1H), 7.37 – 7.23 (m, 3H), 7.20 (d, J = 8.6 Hz, 2H), 6.65 (d, J = 8.6 Hz, 2H), 5.08 (s, 1H), 3.41 (s, 2H), 3.24 (t, J = 6.3 Hz, 2H), 2.47 (dd, J = 14.0, 7.5 Hz, 6H), 2.18 (s, 6H), 1.96 – 1.74 (m, 2H), 1.74 – 1.57 (m, 4H), 1.49 (d, J = 5.1 Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3): δ 147.8, 142.7, 136.5, 130.5, 130.1, 130, 129.7, 126.6, 126.5, 112.0, 61.0, 58.3, 54.7, 45.4, 43.9, 26.2, 25.8, 24.5. LCMS m/z calc for

[M+H]⁺: 352.3, found 352.3. HR-MS: m/z Calculated: 352.2747, found: 352.2743 [M+H]⁺ = C₂₃H₃₄N₃.

6-Nitro-3*H*-1,3-benzoxazol-2-one (**45**)

70% Nitric acid (50 mL, 0.80 mol) was cooled to 0 °C and 3*H*-1,3-benzoxazol-2-one (5.00 g, 37 mmol) was added. The reaction mixture was stirred at rt for 4 h and then poured in ice. The resulting precipitate was collected by filtration, washed with water and dried to give a pink solid (5.80 g, 32.5 mmol, 87 %). Mp > 250 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.41 (s, 1H), 8.20 (d, *J* = 2.2 Hz, 1H), 8.13 (dd, *J* = 8.6 Hz, *J* = 2.2 Hz, 1H), 7.28 (d, *J* = 8.6 Hz, 1H). ¹³C NMR (300 MHz, DMSO-*d*₆): δ 154.7, 143.2, 142.5, 137.2, 121.2, 109.8, 105.8. LCMS m/z calc for [M-H]⁺: 179.0, found: 179.0.

6-Nitro-3-[3-(piperidin-1-yl)propyl]-1,3-benzoxazol-2-one (**46**)

6-Nitro-3*H*-1,3-benzoxazol-2-one (**45**) (6.30 g, 35 mmol) was suspended in ACN (150 mL) and K₂CO₃ (6.91 g, 50 mmol) was added. The reaction mixture was stirred at 80 °C for 30 min. 3-Chloropropylpiperidine hydrochloride (3.96 g, 20 mmol) was added and the reaction mixture was stirred at 80 °C for another 5 h. The inorganics were removed by filtration and the solvent was evaporated. The residue was purified by flash chromatography (DCM/MeOH(NH₃), 9.8:0.2 (v/v)) to give compound **46** as a beige solid (5.98 g, 19.6 mmol, 98%). Mp 81.1 – 81.7 °C. ¹H NMR (300 MHz, CDCl₃): δ 8.21 (dd, *J* = 8.7 Hz, *J* = 2.1 Hz, 1H), 8.10 (d, *J* = 2.1 Hz, 1H), 7.25 (d, *J* = 8.7 Hz, 1H), 4.00 (t, *J* = 6.5 Hz, 2H), 2.38 – 2.28 (m, 6H), 2.02 – 1.98 (m, 2H), 1.56 – 1.53 (m, 4H), 1.45 – 1.41 (m, 2H). ¹³C NMR (75 MHz, CDCl₃): δ 154.1, 143.0, 141.9, 137.3, 120.7, 108.0, 106.1, 55.4, 54.4, 41.1, 25.9, 24.4, 24.3. LCMS m/z calc for [M+H]⁺: 306.2, found: 306.2.

5-Nitro-2-([3-(piperidin-1-yl)propyl]amino)phenol (**47**)

To a solution of 6-nitro-3-[3-(piperidin-1-yl)propyl]-1,3-benzoxazol-2-one (**46**) (1.0 g, 3.28 mmol) in dioxane (5 mL), aqueous 2.5N NaOH (26 mL, 65.5 mmol) was added. The mixture was stirred at 20 °C for 48 h. After cooling to 0 °C, a 1N HCl solution was added to reach pH 8. After 30 min of stirring, the mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were dried over MgSO₄ and evaporated. The residue was purified by flash chromatography (DCM/MeOH(NH₃), 9.5:0.5 (v/v)) to give compound **47** as an orange solid (715 mg, 2.56 mmol, 78%). Mp: 152.3 – 153.0 °C. ¹H NMR (300 MHz, CDCl₃): δ 7.69 (dd, *J* = 8.7 Hz, *J* = 2.4 Hz, 1H), 7.49 (d, *J* = 2.4 Hz, 1H), 6.32 (d, *J* = 8.8 Hz, 1H), 3.23 (t, *J* =

6.5 Hz, 2H); 2.67 – 2.57 (m, 6H), 1.95 – 1.91 (m, 2H), 1.71 – 1.67 (m, 4H), 1.53 – 1.48 (m, 2H). ¹³C NMR (75 MHz, CDCl₃): δ 145.4, 144.3, 136.7, 118.5, 108.8, 106.4, 56.3, 54.1, 41.2, 25.1, 24.5, 23.5. LCMS *m/z* calc for [M+H]⁺: 280.2, found: 280.1.

4-Nitro-2-[2-(piperidin-1-yl)ethoxy]-*N*-[3-(piperidin-1-yl)propyl]aniline (**48**)

5-Nitro-2-([3-(piperidin-1-yl)propyl]amino)phenol (**47**) (200 mg, 0.72 mmol) was suspended in ACN (6 mL) and K₂CO₃ (300 mg, 2.15 mmol) was added. The reaction mixture was stirred at rt for 10 min. 1-(2-Chloroethyl)piperidine hydrochloride (160 mg, 0.86 mmol) was then added and the reaction mixture was stirred at 60 °C for another 5 h. The inorganics were removed by filtration and the solvent was evaporated. The residue was purified by flash chromatography (DCM/MeOH(NH₃), 9.8:0.2 (v/v)) to give a brown oil (200 mg, 0.52 mmol, 72%). ¹H NMR (300 MHz, CDCl₃): δ 7.86 (dd, *J* = 8.9 Hz, *J* = 2.4 Hz, 1H), 7.62 (d, *J* = 2.4 Hz, 1H), 6.46 (d, *J* = 8.9 Hz, 1H), 6.19 (br t, *J* = 4.9 Hz, 1H), 4.17 (t, *J* = 6.1 Hz, 2H), 3.28 (m, 2H), 2.77 (t, *J* = 5.8 Hz, 2H), 2.48 (m, 4H), 2.45 – 2.33 (m, 6H), 1.85 – 1.82 (m, 2H), 1.65 – 1.54 (m, 8H), 1.49 – 1.39 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 145.1, 144.3, 136.3, 120.3, 106.48, 106.3, 66.4, 57.6, 57.2, 54.8, 54.5, 42.0, 25.8, 25.7, 24.2. LCMS *m/z* calc for [M+H]⁺: 391.3, found: 391.1.

2-[2-(Piperidin-1-yl)ethoxy]-*N*-[3-(piperidin-1-yl)propyl]benzene-1,4-diamine (**49**)

4-Nitro-2-[2-(piperidin-1-yl)ethoxy]-*N*-[3-(piperidin-1-yl)propyl]aniline (**48**) (100 mg, 0.255 mmol) was dissolved in MeOH (5 mL). Pd/C 10 % (20 mg, 7 mol%) was added and the reaction mixture was stirred at 40 °C for 30 min. The catalyst was filtered through a celite pad and the filtrate was evaporated to give **49** as a purple oil which was used in the next step without further purification. ¹H NMR (300 MHz, CDCl₃): δ 6.43 (d, *J* = 8.2 Hz, 1H), 6.30 – 6.20 (m, 2H), 4.03 (t, *J* = 6.3 Hz, 2H), 3.63 (br s, 3H), 3.06 (t, *J* = 7.1 Hz), 2.74 (t, *J* = 6.3 Hz, 2H), 2.47 – 2.44 (m, 4H), 2.42 – 2.31 (m, 6H), 1.78 – 1.73 (m, 2H), 1.62 – 1.52 (m, 8H), 1.47 – 1.35 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 147.2, 137.3, 131.8, 111.8, 108.0, 111.4, 66.3, 58.0, 57.5, 55.0, 54.7, 43.5, 26.7, 26.0, 24.3. LCMS *m/z* calc for [M+H]⁺: 361.3, found: 361.1.

1-(3-[2-(Piperidin-1-yl)ethoxy]-4-([3-(piperidin-1-yl)propyl]amino)phenyl)-1*H*-pyrrole-3-carbaldehyde (**50**)

2-[2-(Piperidin-1-yl)ethoxy]-*N*-[3-(piperidin-1-yl)propyl]benzene-1,4-diamine (**49**) was dissolved in acetic acid (5 mL). 2,5-Dimethoxy-3-formyl-2,3,4,5-tetrahydrofuran (380 μL, 2.71 mmol) was added and the reaction mixture was heated at 90 °C for 2 h. The solvent was then

evaporated and the residue taken up in saturated NaHCO₃ solution (50 mL). The aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over MgSO₄ and evaporated. The residue was purified by flash chromatography (DCM/MeOH(NH₃), 9.8:0.2 (v/v)) to afford **50** as a brown oil (410 mg, 0.93 mmol, 43 %). ¹H NMR (300 MHz, CDCl₃): δ 9.81 (s, 1H), 7.54 (dd, *J* = 2.1 Hz, *J* = 1.7 Hz, 1H), 6.95 (dd, *J* = 2.9 Hz, *J* = 2.2 Hz, 1H), 6.89 (dd, *J* = 8.2 Hz, *J* = 2.3 Hz, 1H), 6.81 (d, *J* = 2.3 Hz, 1H), 6.74 (dd, *J* = 2.8 Hz, *J* = 1.8 Hz, 1H), 6.59 (d, *J* = 8.4 Hz, 1H), 4.91 (br s, 1H), 4.15 (t, *J* = 6.1 Hz, 2H), 3.21 (t, *J* = 6.6 Hz, 2H), 2.80 (t, *J* = 6.2 Hz, 2H), 2.59 – 2.35 (m, 10H), 1.84 – 1.89 (m, 2H), 1.69 – 1.53 (m, 8H), 1.53 – 1.38 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 185.5, 146.3, 138.5, 129.0, 127.7, 127.3, 123.0, 114.8, 109.3, 108.9, 105.8, 66.8, 57.9, 57.4, 55.0, 54.7, 42.5, 26.2, 25.9, 24.2. LCMS *m/z* calc for [M+H]⁺: 439.3, found: 439.2.

4-(3-[(Dimethylamino)methyl]-1H-pyrrol-1-yl)-2-[2-(piperidin-1-yl)ethoxy]-*N*-[3-(piperidin-1-yl) propyl]aniline (**51**)

To a solution of 1-(3-[2-(piperidin-1-yl)ethoxy]-4-([3-(piperidin-1-yl)propyl]amino)phenyl)-1*H*-pyrrole-3-carbaldehyde (**50**) (85 mg, 0.19 mmol) in DCE (2 mL), dimethylamine in THF (2M, 144 μL, 0.29 mmol) was added. After 1 h 30 of stirring at rt, NaBH(OAc)₃ (61 mg, 0.29 mmol) and acetic acid (17 μL, 0.29 mmol) were added. After 5 h at rt, saturated NaHCO₃ solution was added. The reaction mixture was stirred for another 1 h. DCM was added and the layers were separated. The organic layer was washed twice with saturated NaHCO₃ solution. The organic layer was dried over MgSO₄ and evaporated. The residue was purified by semi-preparative chromatography (eluent H₂O formic, ACN formic, 9:1 to 1:9 (v/v)). to afford compound 51 as a yellow oil (28 mg, 0.06 mmol, 31%). ¹H NMR (300 MHz, CDCl₃): δ 6.91 – 6.85 (m, 3H), 6.82 (d, *J* = 2.3 Hz, 1H), 6.58 (d, *J* = 8.4 Hz, 1H), 6.23 (dd, *J* = 2.0 Hz, *J* = 2.1 Hz, 1H), 4.68 (br s, 1H), 4.15 (t, *J* = 6.2 Hz, 2H), 3.40 (s, 2H), 3.19 (t, *J* = 6.7 Hz, 2H), 2.80 (t, *J* = 6.2 Hz, 2H), 2.53 – 2.41 (m, 10H), 2.29 (s, 6H), 1.87 – 1.84 (m, 2H), 1.65 – 1.58 (m, 8H), 1.49 – 1.42 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 146.3, 137.1, 130.9, 121.4, 119.5, 113.9, 110.5, 109.7, 105.5, 66.7, 57.9, 57.5, 56.5, 54.9; 45.0, 42.7, 26.5, 26.0, 24.4. LCMS *m/z* calc for [M+H]⁺: 468.4, found: 468.3. HR-MS: *m/z* Calculated: 468.3697, found: 468.3696 [M+H]⁺ = C₂₈H₄₆ON₅O.

4.2 Computational methods

Training chemical dataset. An in-house dataset including 51 compounds from series A and 35 from series B was used for the computation of pharmacophore models for inhibition of Aβ₁.

42 secretion (Table S1, Figure S1). Sketching, 3D conversion and conformer generation of the 86 molecules was performed with ChemAxon (Marvin 14.8.11, 2014, <http://www.chemaxon.com>).

Pharmacophore detection. Common pharmacophore features were generated from training set using *Align-It* program [36] onto a linux workstation for pharmacophore perception of anti-A β ₁₋₄₂ compounds. This program takes advantage of detection of positively charged atoms and allows to customize the nature of pharmacophore features by specifying the argument *funcGroup CHARGE*. In this, hydrogen bond donor features were not taken into account in order to avoid the redundant and non-informative features because of overlapping with positive charge features. We chose a 3-features (Positive/Positive/Aromatic) or a more restrictive 4-features (Positive/Positive/Positive/ Aromatic) layout for generation of pharmacophores models. B_1 and B_10 were chosen as templates for 3D flexible superimposition of other molecules. Among the 86 molecules of the entire dataset, pharmacophore detection was computed from a reduced set of molecules including only highly active (HA) compounds or from a larger set including also moderately active (HMA) compounds for anti-A β ₁₋₄₂ activities.

Pharmacophore evaluation. Learned only from active molecules, 3D pharmacophore models were evaluated by their efficiency to discriminate active and inactive compounds. Briefly, the robustness of pharmacophore models was evaluated by screening all the conformers of 86 reference molecules against 3D pharmacophore models with *Align-it* program. The matching molecules were ranked according to a Tanimoto fitting value between pharmacophore features and concerned atoms of fitted molecules whereas for each non-matched molecule was conferred an arbitrary high RMSD value. ROC scores depict the area under the curve of the plot true positive = f(false positives) according to ranking (Table S4).

4.3 Biological evaluations

Antibodies. Primary antibodies used in this study for western-blot analysis included a well-characterized homemade rabbit antiserum against the last 17 amino acids of APP, named APP-Cter-C17 (1/5000) [14,19,37]. Anti- β -actin (1/10 000) was obtained from Sigma. Anti-LC3B (1/2000) and anti-p62/SQSTM1 (1/2000) antibodies were purchased from Cell Signaling Technology. Secondary antibodies (peroxidase-labelled goat anti-rabbit IgG, 1/5000 or peroxidase-labelled horse anti-mouse IgG, 1/50000) were obtained from Vector Laboratories.

Cell culture and treatment. The human neuroblastoma cell line SY5Y-APP^{695WT} was maintained in Dulbecco's modified Eagle medium (DMEM, high glucose, pyruvate – GIBCO, Life Technologies) supplemented with 10% foetal bovine serum, 2 mM L-glutamine, 1 mM non-essential amino acids and penicillin/streptomycin (GIBCO, Life Technologies) at 37 °C in a 5% CO₂ humidified incubator [14]. For compounds treatment, a 10 mM stock solution was diluted in freshly supplemented DMEM medium to obtain the precise final concentration of drug. Bafilomycin A1 (Baf_{A1}), the vacuolar 362 type H⁺ ATPase inhibitor, was purchased from Merck Millipore and was used at a final dilution of 100 nM. Cells were plated at a density of 5.10⁵ cells per well into 12-well plates and cultured with 1 mL supplemented DMEM cell medium for 24 h before drug exposure. The following day, cell medium was replaced with fresh medium containing drugs diluted at the indicated concentrations. Cells were treated for 24 h. At the end of treatments, the cell medium was collected and kept at -80 °C until use, cells were rinsed once with PBS and extracted in 100 µL of Laemmli buffer (10 mM Tris, 20% glycerol and 2% Sodium dodecyl sulfate) using a cell-scraper. The cell lysate was further sonicated (30 pulses of 0.5 s, 60 Hz) for 5 min. Total protein concentration was determined using the Pierce BCA Protein Assay Kit (Thermo scientific) according to the manufacturer's instructions. Samples were stored at -80 °C until analysis.

Primary neuronal cultures and drug treatment. Primary neuron cultures were obtained from C57BL6 wild-type mice as described previously [38]. Briefly, females were sacrificed at 18.5 days of gestation to collect forebrains of fetuses. Dissection was performed under a microscope in ice-cold Hank's balanced salt solution containing 0.5% w/v D-glucose and 25 mM Hepes buffer. Cells were dissociated mechanically in dissection medium containing 0.01% w/v papain, 0.1% w/v dispase II, and 0.01% w/v DNase and incubated at 37 °C twice for 10 min. Cells were then centrifuged at 220g for 5 min at 4 °C, resuspended in Neurobasal medium supplemented with 2% B27, 1 mM sodium pyruvate, 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM Glutamax (Invitrogen), filtered through a 40 µm cell strainer, counted, and plated on poly-L-ornithine- and laminin-coated 12-well plates at a density of 5*10⁵ cells per well. New medium was added at a ratio of 1:3 of starting volume every 3 days until the end of experiments. Drug treatments with **30** and **31** at 1, 3 or 5 µM were performed directly in the conditioned cell media for 24 h at 16 days in vitro (DIV).

Cytotoxicity assays. Determination of cell toxicity was assessed by measurement of lactate dehydrogenase (LDH) release (CytoTox 96® Non-Radioactive Cytotoxicity Assay – Promega)

according to the manufacturer's instructions. SY5Y-APP^{695WT} cells were plated into a 96-well plate at 2×10^4 cells per well with 100 μ L of DMEM supplemented medium. Cells were treated as described above and LDH measurement was performed at the end of treatment. Primary neuronal cultures were plated into a 48-well plate at a density of about 1.5×10^5 cells per well with Neurobasal supplemented medium. Cells were cultured and treated as described above. LDH measurement was performed at the end of treatment.

Western Blot Analysis. Cell protein lysates were prepared for western-blot analysis by diluting the sample with 1 volume of NuPAGE® lithium dodecyl sulfate (LDS) 2X sample buffer supplemented with 20% NuPAGE® sample reducing agents (Invitrogen). Samples were heated 10 min at 100 °C. 10 μ g of total proteins per well were loaded onto precast 4-12% Criterion XT Bis-Tris polyacrylamide gels (Bio-Rad) and electrophoresis was achieved after applying a tension of 150 V during 90 min using a Criterion electrophoresis Cell with the NuPAGE® MOPS SDS running buffer (1X). Proteins were transferred to a nitrocellulose membrane of 0.4 μ m pore size (G&E Healthcare) using the Criterion blotting system and applying a tension of 100 V for 45 min. To resolve proteins of low molecular weights such as carboxy-terminal fragments of APP, 12% Criterion XT Bis-Tris polyacrylamide gels (Bio-Rad) were used and electrophoresis was performed during 70 min at 150 V in a NuPAGE® MES SDS running buffer (1X). Proteins were transferred to a nitrocellulose membrane of 0.2 μ m pore size (G&E Healthcare) at 100 V for 40 min. Molecular weights calibration was achieved using molecular weight markers (Novex and Magic Marks, Life Technologies). Protein transfer and quality were determined by a reversible Ponceau Red coloration (0.2% Xylidine Ponceau Red and 3% Trichloroacetic acid). Membranes were then blocked in 25 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1% Tween-20 (v/v) (TBS-T) and 5% (w/v) of skimmed milk or 5% (w/v) of bovine serum albumin depending on the antibody during 1 h. Membrane was rinsed three-times 10 min in TBS-T before incubation with the primary antibody overnight at 4 °C. Membrane was rinsed 3 times 10 min with TBS-T and then incubated with the secondary antibody for 45 min at room temperature (RT). The immunoreactive complexes were revealed using the ECLTM Western Blotting Detection Reagents (G&E Healthcare) and image acquisitions were performed with the Amersham Imager 600 (G&E Healthcare). Quantifications of protein expression levels were performed with ImageJ Software (NIH).

Quantification of secreted A β _{1-40/1-42} and sAPP α /sAPP β . Conditioned media of SY5Y-APP^{695WT} collected at the end of treatments were centrifuged at 1000g for 5 min to eliminate

cells debris. A β ₁₋₄₀ and A β ₁₋₄₂ peptide concentrations in pg/mL were determined using amyloid-beta 40 and 42 Human ELISA kits (Invitrogen) according to the manufacturer's instructions after 1:10 and 1:2 dilution of supernatants in ELISA buffer, respectively. sAPP α and sAPP β concentrations in ng/mL were determined using the sAPP α /sAPP β kit (Meso Scale Diagnostics, MSD®) according to the manufacturer's instructions.

Immunofluorescence. SY5Y-APP^{695WT} cells were plated at 3x10⁵ cells per well on poly-D-lysine coated glass coverslip with 1 mL of DMEM supplemented medium. Primary neurons were plated at 2.5x10⁵ cells par well with 1 mL of Neurobasal supplemented medium. Treatment with compound **30** at 5 μ M was performed following the same protocols described above. At the end of treatments, cells were fixed with 4% paraformaldehyde in PBS during 15 min at rt and rinsed 3 times 5 min with PBS. Cells were then permeabilized using 0.25% Triton X-100 during 15 min at rt and rinsed with PBS 3 times for 5 min before blocking in 1% BSA in PBS for 1 h at rt. After 3 washes with PBS, cells were incubated with primary antibodies directed against LC3-B (1/200) and p62 (1/200) at 4 °C overnight in a PBS solution containing 1% BSA and 0.02% Triton X-100. The following day, coveslips were rinsed with PBS and incubated with anti-IgG secondary antibodies coupled to Alexa Fluor 568 (1/500) (Invitrogen). Nuclei were visualized using DAPI (Thermo Scientific). Images were acquired on a Zeiss Axio Imager Z2 microscope (Carl Zeiss, Germany) equipped with a Hamamatsu ORCA-Flash4.0 digital camera (Hamamatsu Photonics, Japan) and ApoTome.2 system (Carl Zeiss, Germany). For Apotome image acquisition, the Axio Imager was used with optical plan-apochromat 63x/1.4 oil M27.

β -secretase *in vitro* activity assay. These experiments were performed on human recombinant BACE-1 protein at Eurofins Cerep (Celle-Lévescault, France), with minor variations to the experimental protocol described by Ermolieff, J. et al. [34]. The cleavage of fluorescent Mca-S-E-V-N-L-D-AE-F-R-K(Dnp)-R-R-NH₂ substrate to Mca-S-E-V-N-L-NH₂ was monitored after 60 min incubation at rt in the presence or absence of test molecules. Compounds **30** and **31** were evaluated at concentrations of 1 and 10 μ M. Both compounds were found totally inactive (% inhibition < 10%). Under the assay conditions, reference OM 99-2 displayed an IC₅₀ value of 59 nM.

Statistical Analysis. For statistical analysis, the non-parametric Mann-Whitney test was selected using GraphPad Prism 6 (GraphPad Software) and statistical significance was set at * $p < 0.05$, ** $p < 0.001$, *** $p < 0.001$ and **** $p < 0.0001$. All data are reported as mean $\pm$ SEM.

ASSOCIATED CONTENT

Supporting Information. Supplementary tables S1-S3, figures S1 & S2, ^1H and ^{13}C NMR spectroscopic data and HRMS spectra for all final compounds

Corresponding authors:

Dr. Jamal El Bakali

Inserm UMR-S1172 - Onco and Neurochemistry team, School of Pharmacy, 3 rue du Pr. Laguesse – BP 83 – 59006 Lille cedex – France – Tel +33 (0)3 20 96 49 66.

e-mail : jamal.el-bakali@univ-lille.fr

Dr. Valerie Vingtdeux

Inserm UMR-S1172 - Alzheimer & Tauopathies team – Jean-Pierre Aubert Research Centre - rue M. Polonowski - 59045 Lille cedex – France – Tel + 33(0)3 20 29 88 91

e-mail : valerie.vingtdeux@inserm.fr

Funding Sources

This work was supported by Inserm and the University of Lille. Grants were obtained from ANR (VIDALZ), Laboratory of Excellence Labex DISTALZ and France Alzheimer. Marion Gay, Caroline Evrard and Florian Descamps are the recipient of fellowships from the University of Lille 2. The 300 MHz NMR facilities were funded by the Région Nord Pas-de-Calais (France), the Ministère de la Jeunesse, de l'Éducation Nationale et de la Recherche (MJENR) and the Fonds Européens de Développement Régional (FEDER).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENT

We expressed our thanks to C. Mésangeau, N. Deguine, F. Copper and L. Barber for their contribution in organic synthesis, F. Sauvé, A. Trichies and R. Dufosse for their help with the in vitro experiments. We thank the animal core facility (animal facilities of Université de Lille-Inserm) of “Plateformes en Biologie Santé de Lille” as well as C. Degraeve, M. Besegher-Dumoulin, J. Devassine, R. Dehaynin and D. Taillieu for animal care.

ABBREVIATIONS

AD, Alzheimer’s disease; AICD, APP intracellular domain; APP, amyloid precursor protein; CTF, carboxy-terminal fragment; CQ, chloroquine.

References

- [1] A. Serrano-Pozo, M.P. Frosch, E. Masliah, B.T. Hyman, Neuropathological alterations in Alzheimer disease., Cold Spring Harb. Perspect. Med. 1 (2011) 1–23. doi:10.1101/cshperspect.a006189.
- [2] B. De Strooper, Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process, Physiol. Rev. 90 (2010) 465–494. doi:10.1152/physrev.00023.2009.
- [3] J. Cummings, G. Lee, T. Mortsdorf, A. Ritter, K. Zhong, Alzheimer’s disease drug development pipeline: 2017, Alzheimer’s Dement. Transl. Res. Clin. Interv. 3 (2017) 367–384. doi:10.1016/j.trci.2017.05.002.
- [4] R.J. Andrew, K.A.B. Kellett, G. Thinakaran, N.M. Hooper, A Greek tragedy: The growing complexity of Alzheimer amyloid precursor protein proteolysis, J. Biol. Chem. 291 (2016) 19235–19244. doi:10.1074/jbc.R116.746032.
- [5] H.S. Nhan, K. Chiang, E.H. Koo, The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes, Acta Neuropathol. 129 (2015) 1–19. doi:10.1007/s00401-014-1347-2.
- [6] R. Vassar, D.M. Kovacs, R. Yan, P.C. Wong, The γ -Secretase Enzyme BACE in Health and Alzheimer’s Disease: Regulation, Cell Biology, Function, and Therapeutic Potential, J. Neurosci. 29 (2009) 12787–12794. doi:10.1523/JNEUROSCI.3657-09.2009.
- [7] R. Yan, R. Vassar, Targeting the β secretase BACE1 for Alzheimer’s disease therapy, Lancet Neurol. 13 (2014) 319–329. doi:10.1016/S1474-4422(13)70276-X.
- [8] T. Jonsson, J.K. Atwal, S. Steinberg, J. Snaedal, P. V. Jonsson, S. Bjornsson, H. Stefansson, P. Sulem, D. Gudbjartsson, J. Maloney, K. Hoyte, A. Gustafson, Y. Liu, Y.

- Lu, T. Bhangale, R.R. Graham, J. Huttenlocher, G. Bjornsdottir, O.A. Andreassen, E.G. Jonsson, A. Palotie, T.W. Behrens, O.T. Magnusson, A. Kong, U. Thorsteinsdottir, R.J. Watts, K. Stefansson, A mutation in APP protects against Alzheimer's disease and age-related cognitive decline, *Nature*. 488 (2012) 96–99. doi:10.1038/nature11283.
- [9] J.A. Maloney, T. Bainbridge, A. Gustafson, S. Zhang, R. Kyauk, P. Steiner, M. Van Der Brug, Y. Liu, J.A. Ernst, R.J. Watts, J.K. Atwal, Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein, *J. Biol. Chem.* 289 (2014) 30990–31000. doi:10.1074/jbc.M114.589069.
- [10] A.K. Ghosh, H.L. Osswald, BACE1 (β -secretase) inhibitors for the treatment of Alzheimer's disease, *Chem. Soc. Rev.* 43 (2014) 6765–6813. doi:10.1039/C3CS60460H.
- [11] R. Vassar, BACE1 inhibitor drugs in clinical trials for Alzheimer's disease, *Alzheimer's Res. Ther.* 6 (2014) 1–14. doi:10.1186/s13195-014-0089-7.
- [12] W.J. Netzer, K. Bettayeb, S.C. Sinha, M. Flajolet, P. Greengard, V. Bustos, Gleevec shifts APP processing from a β -cleavage to a nonamyloidogenic cleavage, *Proc. Natl. Acad. Sci.* 114 (2017) 1389–1394. doi:10.1073/pnas.1620963114.
- [13] S. Ben Halima, S. Mishra, K.M.P. Raja, M. Willem, A. Baici, K. Simons, O. Brüstle, P. Koch, C. Haass, A. Caflisch, L. Rajendran, Specific Inhibition of β -Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein, *Cell Rep.* 14 (2016) 2127–2141. doi:10.1016/j.celrep.2016.01.076.
- [14] V. Vingtdeux, M. Hamdane, A. Loyens, P. Gelé, H. Drobeck, S. Bégard, M.C. Galas, A. Delacourte, J.C. Beauvillain, L. Buée, N. Sergeant, Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies, *J. Biol. Chem.* 282 (2007) 18197–18205. doi:10.1074/jbc.M609475200.
- [15] T. Hamano, T.F. Gendron, E. Causevic, S.H. Yen, W.L. Lin, C. Isidoro, M. Deture, L.W. Ko, Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression, *Eur. J. Neurosci.* 27 (2008) 1119–1130. doi:10.1111/j.1460-9568.2008.06084.x.
- [16] J.H.K. Tam, R.M. Cobb, C. Seah, S.H. Pasternak, Tyrosine binding protein sites regulate the intracellular trafficking and processing of amyloid precursor protein through a novel lysosome-directed pathway, *PLoS One*. 11 (2016) 1–24. doi:10.1371/journal.pone.0161445.

- [17] P. Melnyk, V. Vingtdeux, S. Burlet, S. Eddarkaoui, M.E. Grosjean, P.E. Larchanché, G. Hochart, C. Sergheraert, C. Estrella, M. Barrier, V. Poix, P. Plancq, C. Lannoo, M. Hamdane, A. Delacourte, P. Verwaerde, L. Buée, N. Sergeant, Chloroquine and Chloroquinoline Derivatives as Models for the Design of Modulators of Amyloid Peptide Precursor Metabolism, *ACS Chem. Neurosci.* 6 (2015) 559–569. doi:10.1021/cn5003013.
- [18] C. Evrard, P. Kienlen-Campard, R. Opsomer, B. Tasiaux, J.-N. Octave, L. Buée, N. Sergeant, V. Vingtdeux, Contribution of the endosomal-lysosomal and proteasomal systems in Amyloid- β Precursor Protein derived fragments processing, (2018). doi:https://doi.org/10.1101/300921.
- [19] V. Vingtdeux, M. Hamdane, S. Bégard, A. Loyens, A. Delacourte, J.C. Beauvillain, L. Buée, P. Marambaud, N. Sergeant, Intracellular pH regulates amyloid precursor protein intracellular domain accumulation, *Neurobiol. Dis.* 25 (2007) 686–696. doi:10.1016/j.nbd.2006.09.019.
- [20] A.E. González, V.C. Muñoz, V.A. Cavieres, H.A. Bustamante, V.H. Cornejo, Y.C. Januário, I. González, C. Hetz, L.L. Dasilva, A. Rojas-Fernández, R.T. Hay, G.A. Mardones, P. V. Burgos, Autophagosomes cooperate in the degradation of intracellular C-terminal fragments of the amyloid precursor protein via the MVB/lysosomal pathway, *FASEB J.* 31 (2017) 2446–2459. doi:10.1096/fj.201600713R.
- [21] D.J. Klionsky, D.J. Klionsky, K. Abdelmohsen, A. Abe, M.J. Abedin, H. Abeliovich, A.A. Arozena, H. Adachi, C.M. Adams, P.D. Adams, K. Adeli, P.J. Adhihetty, S.G. Adler, G. Agam, R. Agarwal, M.K. Aghi, M. Agnello, P. Agostinis, P. V. Aguilar, J. Aguirre-Ghiso, J. Aguirre-Ghiso, E.M. Airoidi, E.M. Airoidi, S. Ait-Si-Ali, T. Akematsu, E.T. Akporiaye, M. Al-Rubeai, G.M. Albaiceta, C. Albanese, D. Albani, M.L. Albert, J. Aldudo, H. Algül, M. Alirezai, I. Alloza, I. Alloza, A. Almasan, M. Almonte-Beceril, E.S. Alnemri, C. Alonso, N. Altan-Bonnet, D.C. Altieri, S. Alvarez, L. Alvarez-Erviti, S. Alves, G. Amadoro, A. Amano, C. Amantini, S. Ambrosio, I. Amelio, A.O. Amer, M. Amessou, A. Amon, Z. An, F.A. Anania, S.U. Andersen, U.P. Andley, C.K. Andreadi, N. Andrieu-Abadie, A. Anel, D.K. Ann, S. Anoopkumar-Dukie, M. Antonioli, M. Antonioli, H. Aoki, N. Apostolova, S. Aquila, K. Aquilano, K. Araki, E. Arama, A. Aranda, J. Araya, A. Arcaro, E. Arias, H. Arimoto, A.R. Ariosa, J.L. Armstrong, T. Arnould, I. Arsov, K. Asanuma, V. Askanas, E. Asselin, R. Atarashi, S.S. Atherton, J.D. Atkin, L.D. Attardi, P. Auburger, G. Auburger, L. Aurelian, R. Autelli, L. Avagliano, L. Avagliano, M.L. Avantiaggiati, L. Avrahami, S.

Awale, N. Azad, T. Bachetti, J.M. Backer, D.H. Bae, J.S. Bae, O.N. Bae, S.H. Bae, E.H. Baehrecke, S.H. Baek, S. Baghdiguian, A. Bagniewska-Zadworna, H. Bai, J. Bai, X.Y. Bai, Y. Bailly, K.N. Balaji, W. Balduini, A. Ballabio, R. Balzan, R. Banerjee, G. Bánhegyi, H. Bao, B. Barbeau, M.D. Barrachina, E. Barreiro, B. Bartel, A. Bartolomé, D.C. Bassham, M.T. Bassi, R.C. Bast, A. Basu, M.T. Batista, H. Batoko, M. Battino, K. Bauckman, B.L. Baumgarner, K.U. Bayer, R. Beale, J.F. Beaulieu, G.R. Beck, G.R. Beck, C. Becker, J.D. Beckham, P.A. Bédard, P.J. Bednarski, T.J. Begley, C. Behl, C. Behrends, G.M.N. Behrens, K.E. Behrns, E. Bejarano, A. Belaid, F. Belleudi, G. Bénard, G. Berchem, D. Bergamaschi, M. Bergami, B. Berkhout, L. Berliocchi, A. Bernard, M. Bernard, F. Bernassola, A. Bertolotti, A.S. Bess, S. Besteiro, S. Bettuzzi, S. Bhalla, S. Bhattacharyya, S.K. Bhutia, C. Biagosch, M.W. Bianchi, M.W. Bianchi, M.W. Bianchi, M. Biard-Piechaczyk, V. Billes, C. Bincoletto, B. Bingol, S.W. Bird, M. Bitoun, I. Bjedov, C. Blackstone, L. Blanc, G.A. Blanco, H.K. Blomhoff, E. Boada-Romero, S. Böckler, M. Boes, K. Boesze-Battaglia, L.H. Boise, L.H. Boise, A. Bolino, A. Boman, P. Bonaldo, M. Bordi, M. Bordi, J. Bosch, L.M. Botana, J. Botti, G. Bou, M. Bouché, M. Bouchecareilh, M.J. Boucher, M.E. Boulton, S.G. Bouret, P. Boya, M. Boyer-Guittaut, P. V. Bozhkov, N. Brady, V.M.M. Braga, C. Brancolini, G.H. Braus, J.M. Bravo-San-Pedro, J.M. Bravosan-Pedro, J.M. Bravosan-Pedro, J.M. Bravosan-Pedro, L.A. Brennan, E.H. Bresnick, P. Brest, D. Bridges, M.A. Bringer, M. Brini, G.C. Brito, B. Brodin, P.S. Brookes, E.J. Brown, K. Brown, H.E. Broxmeyer, A. Bruhat, A. Bruhat, P.C. Brum, J.H. Brumell, N. Brunetti-Pierri, N. Brunetti-Pierri, R.J. Bryson-Richardson, S. Buch, A.M. Buchan, H. Budak, D. V. Bulavin, D. V. Bulavin, D. V. Bulavin, S.J. Bultman, G. Bultynck, V. Bumbasirevic, Y. Burelle, R.E. Burke, R.E. Burke, M. Burmeister, P. Bütikofer, L. Caberlotto, K. Cadwell, M. Cahova, D. Cai, J. Cai, Q. Cai, S. Calatayud, N. Camougrand, M. Campanella, G.R. Campbell, M. Campbell, S. Campello, S. Campello, R. Candau, I. Caniggia, L. Cantoni, L. Cao, A.B. Caplan, M. Caraglia, C. Cardinali, S.M. Cardoso, J.S. Carew, L.A. Carleton, C.R. Carlin, S. Carloni, S.R. Carlsson, D. Carmona-Gutierrez, L.A.M. Carneiro, O. Carnevali, S. Carra, A. Carrier, B. Carroll, C. Casas, J. Casas, G. Cassinelli, P. Castets, S. Castro-Obregon, G. Cavallini, I. Ceccherini, F. Cecconi, F. Cecconi, F. Cecconi, A.I. Cederbaum, V. Ceña, V. Ceña, S. Cenci, S. Cenci, C. Cerella, D. Cervia, S. Cetrullo, H. Chaachouay, H.J. Chae, A.S. Chagin, C.Y. Chai, C.Y. Chai, G. Chakrabarti, G. Chamilos, E.Y.W. Chan, M.T.V. Chan, D. Chandra, P. Chandra, C.P. Chang, R.C.C. Chang, T.Y. Chang, J.C. Chatham, S. Chatterjee, S. Chauhan, Y. Che, M.E. Cheetham,

R. Cheluvappa, C.J. Chen, G. Chen, G. Chen, G.C. Chen, G. Chen, H. Chen, J.W. Chen, J.K. Chen, J.K. Chen, M. Chen, M. Chen, P. Chen, Q. Chen, Q. Chen, S. Der Chen, S. Chen, S.S.L. Chen, W. Chen, W.J. Chen, W.Q. Chen, W. Chen, X. Chen, Y.H. Chen, Y.G. Chen, Y. Chen, Y. Chen, Y. Chen, Y. Chen, Y.J. Chen, Y.Q. Chen, Y. Chen, Z. Chen, Z. Chen, A. Cheng, C.H.K. Cheng, H. Cheng, H. Cheong, S. Cherry, J. Chesney, C.H.A. Cheung, E. Chevet, H.C. Chi, S.G. Chi, F. Chiacchiera, H.L. Chiang, R. Chiarelli, M. Chiariello, M. Chiariello, M. Chiariello, M. Chieppa, L.S. Chin, M. Chiong, G.N.C. Chiu, D.H. Cho, S.G. Cho, W.C. Cho, Y.Y. Cho, Y.S. Cho, A.M.K. Choi, E.J. Choi, E.K. Choi, E.K. Choi, E.K. Choi, E.K. Choi, J. Choi, M.E. Choi, S. Il Choi, S. Il Choi, T.F. Chou, S. Chouaib, D. Choubey, V. Choubey, K.C. Chow, K. Chowdhury, C.T. Chu, T.H. Chuang, T. Chun, H. Chung, T. Chung, Y.L. Chung, Y.J. Chwae, V. Cianfanelli, R. Ciarcia, I.A. Ciechomska, M.R. Ciriolo, M. Cirone, S. Claerhout, S. Claerhout, M.J. Clague, J. Clària, P.G.H. Clarke, R. Clarke, E. Clementi, E. Clementi, C. Cleyrat, M. Cnop, E.M. Coccia, T. Cocco, P. Codogno, J. Coers, E.E.W. Cohen, D. Colecchia, D. Colecchia, D. Colecchia, L. Coletto, N.S. Coll, E. Colucci-Guyon, S. Comincini, M. Condello, K.L. Cook, G.H. Coombs, C.D. Cooper, J.M. Cooper, I. Coppens, M.T. Corasaniti, M. Corazzari, M. Corazzari, R. Corbalan, E. Corcelle-Termeau, M.D. Cordero, C. Corral-Ramos, O. Corti, O. Corti, A. Cossarizza, P. Costelli, S. Costes, S.L. Cotman, A. Coto-Montes, S. Cottet, S. Cottet, E. Couve, L.R. Covey, L.A. Cowart, J.S. Cox, F.P. Coxon, C.B. Coyne, M.S. Cragg, R.J. Craven, T. Crepaldi, J.L. Crespo, A. Criollo, V. Crippa, M.T. Cruz, A.M. Cuervo, J.M. Cuezva, T. Cui, P.R. Cutillas, M.J. Czaja, M.F. Czyzyk-Krzeska, R.K. Dagda, U. Dahmen, C. Dai, W. Dai, Y. Dai, K.N. Dalby, L.D. Valle, G. Dalmasso, M. D'amelio, M. Damme, A. Darfeuille-Michaud, C. Dargemont, V.M. Darley-Usmar, S. Dasarathy, B. Dasgupta, S. Dash, C.R. Dass, H.M. Davey, L.M. Davids, D. Dávila, R.J. Davis, T.M. Dawson, T.M. Dawson, V.L. Dawson, P. Daza, J. de Belleruche, P. de Figueiredo, P. de Figueiredo, R.C.B.Q. de Figueiredo, J. de la Fuente, L. De Martino, A. De Matteis, G.R.Y. De Meyer, A. De Milito, M. De Santi, W. de Souza, V. De Tata, D. De Zio, J. Debnath, R. Dechant, J.P. Decuypere, J.P. Decuypere, S. Deegan, B. Dehay, B. Del Bello, D.P. Del Re, R. Delage-Mourroux, L.M.D. Delbridge, L. Deldicque, E. Delorme-Axford, Y. Deng, J. Dengjel, M. Denizot, P. Dent, C.J. Der, V. Deretic, B. Derrien, E. Deutsch, T.P. Devarenne, R.J. Devenish, S. Di Bartolomeo, N. Di Daniele, F. Di Domenico, A. Di Nardo, S. Di Paola, A. Di Pietro, L. Di Renzo, A. Di Antonio, G. Díaz-Araya, I. Díaz-Laviada, M.T. Diaz-Meco, J. Diaz-Nido, C.A.

Dickey, R.C. Dickson, M. Diederich, P. Digard, I. Dikic, S.P. Dinesh-Kumar, C. Ding, W.X. Ding, Z. Ding, L. Dini, J.H.W. Distler, A. Diwan, M. Djavaheri-Mergny, K. Dmytruk, R.C.J. Dobson, V. Doetsch, K. Dokladny, S. Dokudovskaya, M. Donadelli, X.C. Dong, X. Dong, Z. Dong, T.M. Donohue, T.M. Donohue-Jr, K.S. Doran, G. D'orazi, G.W. Dorn, V. Dosenko, S. Dridi, L. Drucker, J. Du, L.L. Du, L. Du, A. du Toit, P. Dua, L. Duan, P. Duann, V.K. Dubey, M.R. Duchen, M.A. Duchosal, H. Duez, I. Dugail, V.I. Dumit, M.C. Duncan, E.A. Dunlop, W.A. Dunn, N. Dupont, L. Dupuis, L. Dupuis, R. V. Durán, T.M. Durcan, S. Duvezin-Caubet, U. Duvvuri, V. Eapen, D. Ebrahimi-Fakhari, A. Echard, L. Eckhart, C.L. Edelstein, A.L. Edinger, L. Eichinger, T. Eisenberg, A. Eisenberg-Lerner, N.T. Eissa, W.S. El-Deiry, V. El-Khoury, Z. Elazar, H. Eldar-Finkelman, C.J.H. Elliott, E. Emanuele, U. Emmenegger, N. Engedal, A.M. Engelbrecht, S. Engelender, J.M. Enserink, R. Erdmann, J. Erenpreisa, R. Eri, J.L. Eriksen, A. Erman, R. Escalante, E.L. Eskelinen, L. Espert, L. Esteban-Martínez, T.J. Evans, M. Fabri, G. Fabrias, C. Fabrizi, A. Facchiano, N.J. Færgeman, A. Faggioni, W.D. Fairlie, W.D. Fairlie, W.D. Fairlie, C. Fan, D. Fan, J. Fan, S. Fang, M. Fanto, A. Fanzani, T. Farkas, M. Faure, F.B. Favier, F.B. Favier, H. Fearnhead, M. Federici, E. Fei, T.C. Felizardo, H. Feng, Y. Feng, Y. Feng, Y. Feng, T.A. Ferguson, Á.F. Fernández, M.G. Fernandez-Barrena, J.C. Fernandez-Checa, J.C. Fernandez-Checa, A. Fernández-López, M.E. Fernandez-Zapico, O. Feron, E. Ferraro, C.V. Ferreira-Halder, L. Fesus, R. Feuer, F.C. Fiesel, E.C. Filippi-Chiela, G. Filomeni, G. Filomeni, G.M. Fimia, G.M. Fimia, J.H. Fingert, J.H. Fingert, S. Finkbeiner, S. Finkbeiner, T. Finkel, F. Fiorito, F. Fiorito, P.B. Fisher, M. Flajolet, F. Flamigni, O. Florey, S. Florio, R.A. Floto, M. Folini, C. Follo, E.A. Fon, F. Fornai, F. Fornai, F. Fortunato, A. Fraldi, R. Franco, A. Francois, A. Francois, A. François, L.B. Frankel, I.D.C. Fraser, N. Frey, D.G. Freyssenet, C. Frezza, S.L. Friedman, D.E. Frigo, D.E. Frigo, D. Fu, J.M. Fuentes, J. Fueyo, Y. Fujitani, Y. Fujiwara, M. Fujiya, M. Fukuda, S. Fulda, C. Fusco, B. Gabryel, M. Gaestel, P. Gailly, M. Gajewska, S. Galadari, S. Galadari, G. Galili, I. Galindo, M.F. Galindo, G. Galliciotti, L. Galluzzi, L. Galluzzi, L. Galluzzi, L. Galluzzi, L. Galluzzi, V. Galy, N. Gammoh, S. Gandy, S. Gandy, A.K. Ganesan, S. Ganesan, I.G. Ganley, M. Gannagé, F.B. Gao, F. Gao, J.X. Gao, L.G. Nannig, E.G. Vescovi, M. Garcia-Macía, C. Garcia-Ruiz, A.D. Garg, P.K. Garg, R. Gargini, N.C. Gassen, D. Gatica, D. Gatica, E. Gatti, E. Gatti, E. Gatti, J. Gavard, E. Gavathiotis, L. Ge, P. Ge, S. Ge, P.W. Gean, V. Gelmetti, A.A. Genazzani, J. Geng, P. Genschik, L. Gerner, J.E. Gestwicki, D.A. Gewirtz, S. Ghavami, E. Ghigo, D. Ghosh,

A.M. Giammarioli, A.M. Giammarioli, F. Giampieri, C. Giampietri, A.
 Giatromanolaki, D.J. Gibbings, L. Gibellini, S.B. Gibson, V. Ginet, A. Giordano, A.
 Giordano, F. Giorgini, E. Giovannetti, E. Giovannetti, S.E. Girardin, S. Gispert, S.
 Giuliano, S. Giuliano, C.L. Gladson, A. Glavic, M. Gleave, N. Godefroy, R.M. Gogal,
 K. Gokulan, G.H. Goldman, D. Goletti, M.S. Goligorsky, A. V. Gomes, L.C. Gomes,
 H. Gomez, C. Gomez-Manzano, R. Gómez-Sánchez, D.A.P. Gonçalves, E. Goncu, Q.
 Gong, C. Gongora, C.B. Gonzalez, P. Gonzalez-Alegre, P. Gonzalez-Cabo, P.
 Gonzalez-Cabo, R.A. González-Polo, I.S. Goping, C. Gorbea, N. V. Gorbunov, D.R.
 Goring, A.M. Gorman, S.M. Gorski, S.M. Gorski, S. Goruppi, S. Goto-Yamada, C.
 Gotor, R.A. Gottlieb, I. Gozes, D. Gozuacik, Y. Graba, M. Graef, G.E. Granato, G.D.
 Grant, S. Grant, G.L. Gravina, D.R. Green, A. Greenhough, M.T. Greenwood, B.
 Grimaldi, F. Gros, C. Grose, J.F. Groulx, F. Gruber, P. Grumati, P. Grumati, T. Grune,
 J.L. Guan, K.L. Guan, B. Guerra, C. Guillen, C. Guillen, K. Gulshan, J. Gunst, C. Guo,
 L. Guo, M. Guo, W. Guo, X.G. Guo, A.A. Gust, Å.B. Gustafsson, E. Gutierrez, M.G.
 Gutierrez, H.S. Gwak, A. Haas, J.E. Haber, S. Hadano, M. Hagedorn, D.R. Hahn, A.J.
 Halayko, A. Hamacher-Brady, K. Hamada, A. Hamai, A. Hamann, M. Hamasaki, I.
 Hamer, Q. Hamid, E.M. Hammond, F. Han, W. Han, J.T. Handa, J.A. Hanover, M.
 Hansen, M. Harada, L. Harhaji-Trajkovic, J.W. Harper, A.H. Harrath, A.L. Harris, J.
 Harris, U. Hasler, P. Hasselblatt, K. Hasui, R.G. Hawley, T.S. Hawley, C. He, C.Y. He,
 F. He, G. He, R.R. He, X.H. He, Y.W. He, Y.Y. He, J.K. Heath, M.J. Hébert, R.A.
 Heinzen, G.V. Helgason, M. Hensel, E.P. Henske, C. Her, P.K. Herman, A. Hernández,
 C. Hernandez, S. Hernández-Tiedra, C. Hetz, C. Hetz, P.R. Hiesinger, K. Higaki, S.
 Hilfiker, B.G. Hill, J.A. Hill, W.D. Hill, W.D. Hill, W.D. Hill, W.D. Hill, K. Hino, D.
 Hofius, P. Hofman, G.U. Höglinger, G.U. Höglinger, J. Höhfeld, M.K. Holz, M.K.
 Holz, Y. Hong, D.A. Hood, J.J.M. Hoozemans, T. Hoppe, C. Hsu, C.Y. Hsu, L.C. Hsu,
 D. Hu, G. Hu, H.M. Hu, H. Hu, M.C. Hu, Y.C. Hu, Z.W. Hu, F. Hua, Y. Hua, C.
 Huang, C. Huang, H.L. Huang, K.H. Huang, K.Y. Huang, S. Huang, S. Huang, W.P.
 Huang, Y.R. Huang, Y. Huang, Y. Huang, T.B. Huber, T.B. Huber, T.B. Huber, P.
 Huebbe, W.K. Huh, J.J. Hulmi, J.J. Hulmi, G.M. Hur, J.H. Hurley, Z. Husak, S.N.A.
 Hussain, S.N.A. Hussain, S. Hussain, J.J. Hwang, S. Hwang, T.I.S. Hwang, A.
 Ichihara, Y. Imai, C. Imbriano, M. Inomata, T. Into, V. Iovane, J.L. Iovanna, R. V.
 Iozzo, N.Y. Ip, J.E. Irazoqui, P. Iribarren, Y. Isaka, A.J. Isakovic, H. Ischiropoulos, H.
 Ischiropoulos, J.S. Isenberg, M. Ishaq, H. Ishida, I. Ishii, J.E. Ishmael, C. Isidoro, K.I.
 Isobe, E. Isono, S. Issazadeh-Navikas, K. Itahana, E. Itakura, A.I. Ivanov, A.K. V. Iyer,

J.M. Izquierdo, Y. Izumi, V. Izzo, V. Izzo, V. Izzo, V. Izzo, M. Jäättelä, N. Jaber, D.J. Jackson, W.T. Jackson, T.G. Jacob, T.S. Jacques, C. Jagannath, A. Jain, A. Jain, N.R. Jana, B.K. Jang, A. Jani, A. Jani, B. Janji, P.R. Jannig, P.J. Jansson, S. Jean, M. Jendrach, J.H. Jeon, N. Jessen, E.B. Jeung, K. Jia, L. Jia, H. Jiang, H. Jiang, L. Jiang, T. Jiang, X. Jiang, X. Jiang, X. Jiang, Y. Jiang, Y. Jiang, Y. Jiang, Y. Jiang, A. Jiménez, C. Jin, H. Jin, L. Jin, M. Jin, M. Jin, S. Jin, U.K. Jinwal, E.K. Jo, T. Johansen, D.E. Johnson, G.V.W. Johnson, J.D. Johnson, E. Jonasch, C. Jones, L.A.B. Joosten, J. Jordan, A.M. Joseph, B. Joseph, A.M. Joubert, D. Ju, J. Ju, H.F. Juan, K. Juenemann, G. Juhász, H.S. Jung, J.U. Jung, Y.K. Jung, H. Jungbluth, H. Jungbluth, H. Jungbluth, M.J. Justice, M.J. Justice, B. Jutten, N.O. Kaakoush, K. Kaarniranta, A. Kaasik, T. Kabuta, B. Kaeffer, K. Kågedal, A. Kahana, S. Kajimura, O. Kakhlon, M. Kalia, D. V. Kalvakolanu, Y. Kamada, K. Kambas, V.O. Kaminsky, H.H. Kampinga, M. Kandouz, C. Kang, C. Kang, R. Kang, T.C. Kang, T. Kanki, T.D. Kanneganti, H. Kanno, A.G. Kanthasamy, M. Kantorow, M. Kaparakis-Liaskos, O. Kapuy, V. Karantza, M.R. Karim, P. Karmakar, A. Kaser, S. Kaushik, T. Kawula, A.M. Kaynar, A.M. Kaynar, P.Y. Ke, Z.J. Ke, J.H. Kehrl, K.E. Keller, J.K. Kemper, A.K. Kenworthy, O. Kepp, A. Kern, S. Kesari, D. Kessel, R. Ketteler, I. do C. Kettelhut, B. Khambu, M.M. Khan, V.K.M. Khandelwal, S. Khare, J.G. Kiang, A.A. Kiger, A. Kihara, A.L. Kim, C.H. Kim, D.R. Kim, D.H. Kim, E.K. Kim, E.K. Kim, H.Y. Kim, H.R. Kim, J.S. Kim, J.H. Kim, J.H. Kim, J.C. Kim, J.H. Kim, J.H. Kim, K.W. Kim, M.D. Kim, M.M. Kim, P.K. Kim, S.W. Kim, S.Y. Kim, Y.S. Kim, Y. Kim, A. Kimchi, A.C. Kimmelman, T. Kimura, J.S. King, K. Kirkegaard, V. Kirkin, L.A. Kirshenbaum, S. Kishi, Y. Kitajima, K. Kitamoto, Y. Kitaoka, K. Kitazato, R.A. Kley, W.T. Klimecki, M. Klinkenberg, J. Klucken, H. Knævelsrud, E. Knecht, L. Knuppertz, J.L. Ko, S. Kobayashi, J.C. Koch, C. Koechlin-Ramonatxo, U. Koenig, Y.H. Koh, K. Köhler, S.D. Kohlwein, M. Koike, M. Komatsu, E. Kominami, D. Kong, H.J. Kong, E.G. Konstantakou, B.T. Kopp, T. Korcsmaros, L. Korhonen, V.I. Korolchuk, N. V. Koshkina, Y. Kou, M.I. Koukourakis, C. Koumenis, A.L. Kovács, T. Kovács, W.J. Kovacs, D. Koya, C. Kraft, D. Krainc, H. Kramer, T. Kravic-Stevovic, W. Krek, C. Kretz-Remy, C. Kretz-Remy, C. Kretz-Remy, R. Krick, M. Krishnamurthy, J. Kriston-Vizi, G. Kroemer, G. Kroemer, G. Kroemer, G. Kroemer, M.C. Kruer, R. Kruger, N.T. Ktistakis, K. Kuchitsu, C. Kuhn, A.P. Kumar, A. Kumar, A. Kumar, D. Kumar, D. Kumar, R. Kumar, S. Kumar, M. Kundu, H.J. Kung, H.J. Kung, A. Kuno, S.H. Kuo, J. Kuret, T. Kurz, T. Kwok, T. Kwok, T.K. Kwon, Y.T. Kwon, I. Kyrmizi, A.R. La Spada, A.R. La

Spada, F. Lafont, T. Lahm, A. Lakkaraju, T. Lam, T. Lamark, S. Lancel, T.H.
 Landowski, D.J.R. Lane, J.D. Lane, C. Lanzi, P. Lapaquette, L.R. Lapierre, J. Laporte,
 J. Laukkarinen, G.W. Laurie, S. Lavandero, S. Lavandero, L. Lavie, M.J. Lavoie,
 B.Y.K. Law, H.K.W. Law, K.B. Law, R. Layfield, P.A. Lazo, P.A. Lazo, L. Le Cam,
 L. Le Cam, L. Le Cam, K.G. Le Roch, H. Le Stunff, H. Le Stunff, V. Leardkamolkarn,
 M. Lecuit, B.H. Lee, C.H. Lee, E.F. Lee, E.F. Lee, E.F. Lee, G.M. Lee, H.J. Lee, H.
 Lee, J.K. Lee, J. Lee, J.H. Lee, J.H. Lee, J.H. Lee, M. Lee, M.S. Lee, P.J. Lee, S.W.
 Lee, S.J. Lee, S.J. Lee, S.Y. Lee, S.H. Lee, S.S. Lee, S.S. Lee, S.J. Lee, S. Lee, Y.R.
 Lee, Y.J. Lee, Y.H. Lee, C. Leeuwenburgh, S. Lefort, R. Legouis, J. Lei, Q.Y. Lei,
 D.A. Leib, G. Leibowitz, I. Lekli, S.D. Lemaire, J.J. Lemasters, M.K. Lemberg, A.
 Lemoine, S. Leng, G. Lenz, P. Lenzi, L.O. Lerman, D.L. Barbato, J.I.J. Leu, H.Y.
 Leung, H.Y. Leung, B. Levine, B. Levine, P.A. Lewis, P.A. Lewis, F. Lezoualch, C.
 Li, F. Li, F.J. Li, J. Li, K. Li, L. Li, M. Li, M. Li, Q. Li, R. Li, S. Li, W. Li, W. Li, X.
 Li, Y. Li, J. Lian, C. Liang, Q. Liang, Y. Liao, J. Liberal, P.P. Liberski, P. Lie, A.P.
 Lieberman, H.J. Lim, K.L. Lim, K.L. Lim, K. Lim, R.T. Lima, R.T. Lima, R.T. Lima,
 C.S. Lin, C.S. Lin, C.F. Lin, F. Lin, F. Lin, F.C. Lin, K. Lin, K.H. Lin, P.H. Lin, T.
 Lin, W.W. Lin, Y.S. Lin, Y. Lin, R. Linden, D. Lindholm, L.M. Lindqvist, P. Lingor,
 A. Linkermann, L.A. Liotta, M.M. Lipinski, V.A. Lira, M.P. Lisanti, P.B. Liton, B.
 Liu, C. Liu, C.F. Liu, F. Liu, H.J. Liu, J. Liu, J.J. Liu, J.L. Liu, K. Liu, L. Liu, L. Liu,
 Q. Liu, R.Y. Liu, S. Liu, S. Liu, W. Liu, X. De Liu, X. Liu, X.H. Liu, X. Liu, X. Liu,
 X. Liu, X. Liu, X. Liu, Y. Liu, Y. Liu, Z. Liu, Z. Liu, J.P. Liuzzi, G. Lizard, M. Ljubic,
 I.J. Lodhi, S.E. Logue, B.L. Lokeshwar, Y.C. Long, S. Lonial, B. Loos, C. López-Otín,
 C. López-Vicario, M. Lorente, P.L. Lorenzi, P.L. Lorenzi, P. Lőrincz, M. Los, M.T.
 Lotze, P.E. Lovat, B. Lu, B. Lu, J. Lu, Q. Lu, S.M. Lu, S. Lu, Y. Lu, F. Luciano, S.
 Luckhart, J.M. Lucocq, P. Ludovico, P. Ludovico, A. Lugea, N.W. Lukacs, J.J. Lum,
 J.J. Lum, J.J. Lum, A.H. Lund, H. Luo, J. Luo, S. Luo, C. Luparello, T. Lyons, J. Ma,
 Y. Ma, Y. Ma, Z. Ma, J. Machado, G.M. Machado-Santelli, F. Macian, G.C.
 MacIntosh, J.P. MacKeigan, K.F. Macleod, J.D. MacMicking, L.A. MacMillan-Crow,
 F. Madeo, M. Madesh, M. Madesh, J. Madrigal-Matute, A. Maeda, T. Maeda, G.
 Maegawa, E. Maellaro, H. Maes, M. Magariños, K. Maiese, T.K. Maiti, L. Maiuri,
 M.C. Maiuri, C.G. Maki, R. Malli, W. Malorni, W. Malorni, A. Maloyan, F. Mami-
 Chouaib, N. Man, N. Man, J.D. Mancias, E.M. Mandelkow, M.A. Mandell, A.A.
 Manfredi, S.N. Manié, C. Manzoni, C. Manzoni, K. Mao, K. Mao, Z. Mao, Z.W. Mao,
 P. Marambaud, A.M. Marconi, Z. Marelja, G. Marfe, M. Margeta, E. Margittai, M.

Mari, F. V. Mariani, C. Marin, S. Marinelli, G. Mariño, I. Markovic, R. Marquez, A.M. Martelli, S. Martens, K.R. Martin, S.J. Martin, S. Martin, M.A. Martin-Acebes, P. Martín-Sanz, C. Martinand-Mari, W. Martinet, J. Martinez, N. Martinez-Lopez, U. Martinez-Outschoorn, M. Martínez-Velázquez, M. Martinez-Vicente, W.K. Martins, W.K. Martins, H. Mashima, J.A. Mastrianni, G. Matarese, G. Matarese, P. Matarrese, R. Mateo, S. Matoba, N. Matsumoto, T. Matsushita, A. Matsuura, T. Matsuzawa, M.P. Mattson, S. Matus, S. Matus, S. Matus, N. Maugeri, C. Mauvezin, A. Mayer, D. Maysinger, G.D. Mazzolini, M.K. McBrayer, K. McCall, C. McCormick, G.M. McInerney, S.C. McIver, S. McKenna, J.J. McMahon, I.A. McNeish, F. Mehta-Grigoriou, J.P. Medema, D.L. Medina, K. Megyeri, M. Mehrpour, J.L. Mehta, Y. Mei, U.C. Meier, A.J. Meijer, A. Meléndez, G. Melino, G. Melino, S. Melino, E.J.T. de Melo, M.A. Mena, M.D. Meneghini, J.A. Menendez, R. Menezes, R. Menezes, L. Meng, L.H. Meng, S. Meng, R. Menghini, A.S. Menko, R.F.S. Menna-Barreto, M.B. Menon, M.A. Meraz-Ríos, G. Merla, L. Merlini, A.M. Merlot, A. Meryk, S. Meschini, J.N. Meyer, M.T. Mi, C.Y. Miao, L. Micale, S. Michaeli, C. Michiels, A.R. Migliaccio, A.S. Mihailidou, A.S. Mihailidou, D. Mijaljica, K. Mikoshiba, E. Milan, E. Milan, L. Miller-Fleming, G.B. Mills, I.G. Mills, I.G. Mills, I.G. Mills, G. Minakaki, B.A. Minassian, X.F. Ming, F. Minibayeva, E.A. Minina, J.D. Mintern, S. Minucci, A. Miranda-Vizuete, C.H. Mitchell, S. Miyamoto, K. Miyazawa, N. Mizushima, K. Mnich, B. Mograbi, S. Mohseni, L.F. Moita, M. Molinari, M. Molinari, M. Molinari, A.B. Møller, B. Mollereau, F. Mollinedo, M. Mongillo, M.M. Monick, S. Montagnaro, C. Montell, C. Montell, D.J. Moore, M.N. Moore, R. Mora-Rodriguez, P.I. Moreira, E. Morel, M.B. Morelli, S. Moreno, M.J. Morgan, A. Moris, Y. Moriyasu, J.L. Morrison, L.A. Morrison, E. Morselli, J. Moscat, P.L. Moseley, S. Mostowy, E. Motori, D. Mottet, J.C. Mottram, C.E.H. Moussa, V.E. Mpakou, H. Mukhtar, J.M.M. Levy, S. Muller, R. Muñoz-Moreno, C. Muñoz-Pinedo, C. Münz, M.E. Murphy, J.T. Murray, A. Murthy, I.U. Mysorekar, I.R. Nabi, M. Nabissi, G.A. Nader, Y. Nagahara, Y. Nagai, K. Nagata, A. Nagelkerke, P. Nagy, S.R. Naidu, S. Nair, H. Nakano, H. Nakatogawa, M. Nanjundan, G. Napolitano, N.I. Naqvi, R. Nardacci, D.P. Narendra, M. Narita, A.C. Nascimbeni, R. Natarajan, L.C. Navegantes, S.T. Nawrocki, T.Y. Nazarko, V.Y. Nazarko, T. Neill, L.M. Neri, M.G. Netea, R.T. Netea-Maier, B.M. Neves, P.A. Ney, I.P. Nezis, H.T.T. Nguyen, H.P. Nguyen, A.S. Nicot, H. Nilsen, H. Nilsen, P. Nilsson, P. Nilsson, M. Nishimura, I. Nishino, M. Niso-Santano, H. Niu, R.A. Nixon, V.C.O. Njar, T. Noda, A.A. Noegel, E.M. Nolte, E. Norberg, K.K. Norga, S.K. Noureini, S.

Notomi, L. Notterpek, K. Nowikovskiy, N. Nukina, T. Nürnberger, V.B. O'donnell, T. O'donovan, P.J. O'dwyer, I. Oehme, C.L. Oeste, M. Ogawa, B. Ogretmen, Y. Ogura, Y.J. Oh, M. Ohmuraya, T. Ohshima, R. Ojha, K. Okamoto, T. Okazaki, F.J. Oliver, K. Ollinger, S. Olsson, D.P. Orban, D.P. Orban, P. Ordonez, I. Orhon, L. Orosz, E.J. O'rourke, H. Orozco, H. Orozco, A.L. Ortega, E. Ortona, L.D. Osellame, J. Oshima, S. Oshima, H.D. Osiewacz, T. Otomo, K. Otsu, J.H.J. Ou, T.F. Outeiro, D.Y. Ouyang, H. Ouyang, M. Overholtzer, M.A. Ozbun, P.H. Ozdinler, B. Ozpolat, C. Pacelli, P. Paganetti, G. Page, G. Pages, U. Pagnini, B. Pajak, B. Pajak, S.C. Pak, K. Pakos-Zebrucka, N. Pakpour, Z. Palková, F. Palladino, K. Pallauf, N. Pallet, M. Palmieri, S.R. Paludan, C. Palumbo, S. Palumbo, O. Pampliega, H. Pan, W. Pan, T. Panaretakis, A. Pandey, A. Pandey, A. Pantazopoulou, Z. Papackova, D.L. Papademetrio, I. Papassideri, A. Papini, N. Parajuli, J. Pardo, V. V. Parekh, G. Parenti, J.I. Park, J. Park, O.K. Park, R. Parker, R. Parlato, R. Parlato, J.B. Parys, K.R. Parzych, K.R. Parzych, J.M. Pasquet, B. Pasquier, K.B.S. Pasumathi, D. Patschan, C. Patterson, S. Pattingre, S. Pattingre, S. Pattison, A. Pause, H. Pavenstädt, F. Pavone, Z. Pedrozo, F.J. Peña, M.A. Peñalva, M. Pende, J. Peng, F. Penna, J.M. Penninger, A. Pensalfini, S. Pepe, G.J.S. Pereira, P.C. Pereira, V.P. de la Cruz, M.E. Pérez-Pérez, D. Pérez-Rodríguez, D. Pérez-Sala, C. Perier, A. Perl, D.H. Perlmutter, I. Perrotta, S. Pervaiz, S. Pervaiz, S. Pervaiz, M. Pesonen, J.E. Pessin, G.J. Peters, M. Petersen, I. Petrache, B.J. Petrof, G. Petrovski, G. Petrovski, G. Petrovski, J.M. Phang, M. Piacentini, M. Pierdominici, P. Pierre, P. Pierre, P. Pierre, P. Pierre, V. Pierrefite-Carle, F. Pietrocola, F. Pietrocola, F. Pietrocola, F. Pietrocola, F.X. Pimentel-Muiños, M. Pinar, B. Pineda, R. Pinkas-Kramarski, M. Pinti, P. Pinton, B. Piperdi, J.M. Piret, L.C. Platanias, L.C. Platanias, H.W. Platta, E.D. Plowey, S. Pöggeler, M. Poirrot, P. Polčic, A. Poletti, A.H. Poon, H. Popelka, B. Popova, I. Poprawa, S.M. Poulouse, J. Poulton, S.K. Powers, T. Powers, M. Pozuelo-Rubio, K. Prak, R. Prange, M. Prescott, M. Priault, S. Prince, R.L. Proia, T. Proikas-Cezanne, H. Prokisch, V.J. Promponas, K. Przyklenk, R. Puertollano, S. Pugazhenth, L. Puglielli, A. Pujol, A. Pujol, A. Pujol, J. Puyal, J. Puyal, D. Pyeon, X. Qi, W. Bin Qian, Z.H. Qin, Y. Qiu, Z. Qu, J. Quadrilatero, F. Quinn, N. Raben, H. Rabinowich, F. Radogna, M.J. Ragusa, M. Rahmani, K. Raina, S. Ramanadham, R. Ramesh, A. Rami, S. Randall-Demllo, F. Randow, F. Randow, H. Rao, V.A. Rao, B.B. Rasmussen, T.M. Rasse, E.A. Ratovitski, P.E. Rautou, P.E. Rautou, P.E. Rautou, P.E. Rautou, S.K. Ray, B. Razani, B. Razani, B.H. Reed, F. Reggiori, M. Rehm, A.S. Reichert, T. Rein, D.J. Reiner, E. Reits, J. Ren, X. Ren, M. Renna, J.E.B. Reusch,

J.E.B. Reusch, J.L. Revuelta, L. Reyes, A.R. Rezaie, R.I. Richards, D.R. Richardson, C. Richetta, M.A. Riehle, B.H. Rihn, Y. Rikihisa, B.E. Riley, G. Rimbach, M.R. Rippo, K. Ritis, F. Rizzi, E. Rizzo, P.J. Roach, J. Robbins, M. Roberge, G. Roca, M.C. Roccheri, S. Rocha, C.M.P. Rodrigues, C.I. Rodríguez, S.R. de Cordoba, N. Rodriguez-Muela, J. Roelofs, V. V. Rogov, T.T. Rohn, B. Rohrer, D. Romanelli, L. Romani, P.S. Romano, M.I.G. Roncero, J.L. Rosa, A. Rosello, K. V. Rosen, K. V. Rosen, P. Rosenstiel, M. Rost-Roszkowska, K.A. Roth, G. Roué, M. Rouis, K.M. Rouschop, D.T. Ruan, D. Ruano, D.C. Rubinsztein, E.B. Rucker, A. Rudich, E. Rudolf, R. Rudolf, M.A. Ruegg, C. Ruiz-Roldan, A.A. Ruparelia, P. Rusmini, D.W. Russ, G.L. Russo, G. Russo, R. Russo, T.E. Rusten, T.E. Rusten, V. Ryabovol, K.M. Ryan, S.W. Ryter, D.M. Sabatini, M. Sacher, M. Sacher, C. Sachse, M.N. Sack, J. Sadoshima, P. Saftig, R. Sagi-Eisenberg, S. Sahni, P. Saikumar, T. Saito, T. Saitoh, K. Sakakura, M. Sakoh-Nakatogawa, Y. Sakuraba, M. Salazar-Roa, P. Salomoni, A.K. Saluja, P.M. Salvaterra, R. Salvioli, A. Samali, A.M.J. Sanchez, J.A. Sánchez-Alcázar, R. Sanchez-Prieto, M. Sandri, M.A. Sanjuan, S. Santaguida, L. Santambrogio, G. Santoni, C.N. Dos Santos, C.N. Dos Santos, S. Saran, M. Sardiello, G. Sargent, P. Sarkar, S. Sarkar, M.R. Sarrias, M.M. Sarwal, C. Sasakawa, M. Sasaki, M. Sass, K. Sato, M. Sato, J. Satriano, N. Savaraj, S. Saveljeva, L. Schaefer, U.E. Schaible, M. Scharl, H.M. Schatzl, R. Schekman, W. Scheper, W. Scheper, W. Scheper, A. Schiavi, A. Schiavi, H.M. Schipper, H.M. Schipper, H. Schmeisser, J. Schmidt, I. Schmitz, I. Schmitz, B.E. Schneider, E.M. Schneider, J.L. Schneider, E.A. Schon, M.J. Schönenberger, A.H. Schönthal, D.F. Schorderet, D.F. Schorderet, B. Schröder, S. Schuck, R.J. Schulze, M. Schwarten, T.L. Schwarz, S. Sciarretta, S. Sciarretta, S. Sciarretta, K. Scotto, A.I. Scovassi, R.A. Screatton, R.A. Screatton, M. Screen, H. Seca, H. Seca, H. Seca, S. Sedej, L. Segatori, L. Segatori, N. Segev, P.O. Seglen, J.M. Seguí-Simarro, J. Segura-Aguilar, I. Seiliez, E. Seki, C. Sell, C.F. Semenkovich, G.L. Semenza, U. Sen, A.L. Serra, A. Serrano-Puebla, H. Sesaki, T. Setoguchi, C. Settembre, J.J. Shacka, A.N. Shajahan-Haq, I.M. Shapiro, S. Sharma, H. She, C.K.J. Shen, C.C. Shen, H.M. Shen, S. Shen, W. Shen, R. Sheng, X. Sheng, Z.H. Sheng, T.G. Shepherd, J. Shi, J. Shi, Q. Shi, Q. Shi, Y. Shi, S. Shibutani, K. Shibuya, Y. Shidoji, J.J. Shieh, C.M. Shih, Y. Shimada, S. Shimizu, D.W. Shin, M.L. Shinohara, M. Shintani, T. Shintani, T. Shioi, K. Shirabe, R. Shiri-Sverdlov, O. Shirihai, G.C. Shore, C.W. Shu, D. Shukla, A.A. Sibirny, A.A. Sibirny, V. Sica, V. Sica, V. Sica, V. Sica, C.J. Sigurdson, E.M. Sigurdsson, P.S. Sijwali, B. Sikorska, W.A. Silveira, S. Silvente-Poirot, G.A. Silverman, J. Simak, T.

Simmet, A.K. Simon, H.U. Simon, C. Simone, M. Simons, A. Simonsen, R. Singh, S. V. Singh, S.K. Singh, D. Sinha, S. Sinha, F.A. Sinicrope, A. Sirko, K. Sirohi, B.J.N. Sishi, A. Sittler, P.M. Siu, E. Sivridis, A. Skwarska, R. Slack, I. Slaninová, N. Slavov, S.S. Smaili, K.S.M. Smalley, D.R. Smith, S.J. Soenen, S.A. Soleimanpour, A. Solhaug, K. Somasundaram, J.H. Son, A. Sonawane, C. Song, F. Song, H.K. Song, J.X. Song, W. Song, K.Y. Soo, A.K. Sood, A.K. Sood, T.W. Soong, V. Soontornniyomkij, M. Sorice, F. Sotgia, D.R. Soto-Pantoja, A. Sotthibundhu, M.J. Sousa, H.P. Spaink, P.N. Span, A. Spang, J.D. Sparks, P.G. Speck, S.A. Spector, C.D. Spies, W. Springer, D.S. Clair, A. Stacchiotti, B. Staels, M.T. Stang, D.T. Starczynowski, P. Starokadomskyy, C. Steegborn, J.W. Steele, L. Stefanis, J. Steffan, C.M. Stellrecht, H. Stenmark, T.M. Stepkowski, S.T. Stern, C. Stevens, B.R. Stockwell, B.R. Stockwell, V. Stoka, Z. Storchova, B. Stork, V. Stratoulis, D.J. Stravopodis, D.J. Stravopodis, P. Strnad, A.M. Strohecker, A.L. Ström, P. Stromhaug, J. Stulik, Y.X. Su, Z. Su, C.S. Subauste, S. Subramaniam, C.M. Sue, S.W. Suh, X. Sui, S. Sukserree, D. Sulzer, F.L. Sun, J. Sun, J. Sun, S.Y. Sun, Y. Sun, Y. Sun, Y. Sun, V. Sundaramoorthy, J. Sung, H. Suzuki, K. Suzuki, N. Suzuki, T. Suzuki, Y.J. Suzuki, M.S. Swanson, C. Swanton, K. Swärd, G. Swarup, S.T. Sweeney, P.W. Sylvester, Z. Szatmari, E. Szegezdi, P.W. Szlosarek, H. Taegtmeier, M. Tafani, E. Taillebourg, S.W.G. Tait, K. Takacs-Vellai, Y. Takahashi, S. Takáts, G. Takemura, N. Takigawa, N.J. Talbot, E. Tamagno, J. Tamburini, C.P. Tan, L. Tan, M.L. Tan, M.L. Tan, M. Tan, Y.J. Tan, Y.J. Tan, K. Tanaka, M. Tanaka, D. Tang, D. Tang, G. Tang, I. Tanida, K. Tanji, B.A. Tannous, J.A. Tapia, I. Tasset-Cuevas, M. Tatar, I. Tavassoly, N. Tavernarakis, N. Tavernarakis, N. Tavernarakis, A. Taylor, G.S. Taylor, G.A. Taylor, G.A. Taylor, G.A. Taylor, G.A. Taylor, J.P. Taylor, M.J. Taylor, E. V. Tchetina, A.R. Tee, F. Teixeira-Clerc, F. Teixeira-Clerc, S. Telang, T. Tencomnao, B.B. Teng, R.J. Teng, F. Terro, G. Tettamanti, A.L. Theiss, A.E. Theron, K.J. Thomas, M.P. Thomé, P.G. Thomes, A. Thorburn, J. Thorner, T. Thum, M. Thumm, T.L.M. Thurston, L. Tian, A. Till, A. Till, J.P.Y. Ting, J.P.Y. Ting, V.I. Titorenko, L. Toker, S. Toldo, S.A. Tooze, I. Topisirovic, I. Topisirovic, M.L. Torgersen, M.L. Torgersen, M.L. Torgersen, L. Torosantucci, A. Torriglia, M.R. Torrisi, C. Tournier, R. Towns, V. Trajkovic, L.H. Travassos, G. Triola, D.N. Tripathi, D. Trisciuglio, R. Troncoso, R. Troncoso, I.P. Trougakos, A.C. Truttmann, K.J. Tsai, M.P. Tschan, Y.H. Tseng, T. Tsukuba, A. Tsung, A.S. Tsvetkov, S. Tu, H.Y. Tuan, M. Tucci, D.A. Tumbarello, B. Turk, V. Turk, R.F.B. Turner, A.A. Tveita, S.C. Tyagi, M. Ubukata, Y. Uchiyama, A. Udelnow, T. Ueno, M. Umekawa, R. Umemiya-Shirafuji,

B.R. Underwood, C. Ungermann, R.P. Ureshino, R. Ushioda, V.N. Uversky, N.L. Uzcátegui, T. Vaccari, M.I. Vaccaro, L. Váchová, H. Vakifahmetoglu-Norberg, R. Valdor, E.M. Valente, F. Vallette, A.M. Valverde, G. Van den Berghe, L. Van Den Bosch, G.R. van den Brink, F.G. van der Goot, I.J. van der Klei, L.J.W. van der Laan, W.G. van Doorn, M. van Egmond, K.L. van Golen, K.L. van Golen, K.L. van Golen, L. Van Kaer, M. van L. Campagne, P. Vandenabeele, W. Vandenberghe, W. Vandenberghe, I. Vanhorebeek, I. Varela-Nieto, M.H. Vasconcelos, M.H. Vasconcelos, M.H. Vasconcelos, R. Vasko, D.G. Vavvas, I. Vega-Naredo, G. Velasco, A.D. Velentzas, P.D. Velentzas, T. Vellai, E. Vellenga, M.H. Vendelbo, K. Venkatachalam, N. Ventura, N. Ventura, S. Ventura, P.S.T. Veras, M. Verdier, B.G. Vertessy, A. Viale, M. Vidal, H.L.A. Vieira, R.D. Vierstra, N. Vigneswaran, N. Vij, M. Vila, M. Vila, M. Vila, M. Villar, V.H. Villar, J. Villarroja, C. Vindis, G. Viola, M.T. Viscomi, G. Vitale, D.T. Vogl, O. V. Voitsekhovskaja, C. von Haefen, K. von Schwarzenberg, D.E. Voth, V. Vouret-Craviari, K. Vuori, J.M. Vyas, C. Waeber, C.L. Walker, M.J. Walker, J. Walter, L. Wan, L. Wan, X. Wan, B. Wang, C. Wang, C.Y. Wang, C. Wang, C. Wang, C. Wang, D. Wang, F. Wang, F. Wang, G. Wang, H.J. Wang, H. Wang, H.G. Wang, H. Wang, H.D. Wang, J. Wang, J. Wang, M. Wang, M.Q. Wang, P.Y. Wang, P. Wang, R.C. Wang, S. Wang, T.F. Wang, X. Wang, X.J. Wang, X.W. Wang, X. Wang, X. Wang, Y. Wang, Y. Wang, Y. Wang, Y.J. Wang, Y. Wang, Y. Wang, Y.T. Wang, Y. Wang, Z.N. Wang, P. Wappner, C. Ward, D.M.V. Ward, G. Warnes, H. Watada, Y. Watanabe, K. Watase, T.E. Weaver, C.D. Weekes, J. Wei, T. Weide, C.C. Weihl, G. Weindl, S.N. Weis, L. Wen, X. Wen, X. Wen, Y. Wen, Y. Wen, B. Westermann, C.M. Weyand, A.R. White, E. White, J.L. Whitton, A.J. Whitworth, J. Wiels, F. Wild, M.E. Wildenberg, T. Wileman, D.S. Wilkinson, S. Wilkinson, D. Willbold, D. Willbold, C. Williams, C. Williams, K. Williams, P.R. Williamson, K.F. Winklhofer, S.S. Witkin, S.E. Wohlgemuth, T. Wollert, E.J. Wolvetang, E. Wong, G.W. Wong, R.W. Wong, V.K.W. Wong, E.A. Woodcock, K.L. Wright, C. Wu, D. Wu, G.S. Wu, J. Wu, J. Wu, M. Wu, M. Wu, S. Wu, W.K.K. Wu, Y. Wu, Z. Wu, C.P.R. Xavier, C.P.R. Xavier, R.J. Xavier, G.X. Xia, T. Xia, W. Xia, W. Xia, Y. Xia, H. Xiao, J. Xiao, S. Xiao, W. Xiao, C.M. Xie, Z. Xie, Z. Xie, M. Xilouri, Y. Xiong, C. Xu, C. Xu, F. Xu, H. Xu, H. Xu, J. Xu, J. Xu, J. Xu, J. Xu, L. Xu, X. Xu, Y. Xu, Y. Xu, Z.X. Xu, Z. Xu, Z. Xu, Y. Xue, T. Yamada, A. Yamamoto, K. Yamanaka, S. Yamashina, S. Yamashiro, B. Yan, B. Yan, X. Yan, Z. Yan, Y. Yanagi, D.S. Yang, J.M. Yang, L. Yang, M. Yang, P.M. Yang, P. Yang, Q. Yang, W. Yang, W.Y. Yang, X. Yang, Y. Yang, Y. Yang, Z. Yang, Z. Yang,

- M.C. Yao, P.J. Yao, X. Yao, Z. Yao, Z. Yao, Z. Yao, L.S. Yasui, M. Ye, B. Yedvobnick, B. Yeganeh, E.S. Yeh, P.L. Yeyati, F. Yi, L. Yi, X.M. Yin, C.K. Yip, Y.M. Yoo, Y.H. Yoo, S.Y. Yoon, K.I. Yoshida, T. Yoshimori, K.H. Young, H. Yu, J.J. Yu, J.T. Yu, J. Yu, L. Yu, W.H. Yu, X.F. Yu, Z. Yu, J. Yuan, Z.M. Yuan, B.Y.J.T. Yue, J. Yue, Z. Yue, D.N. Zacks, E. Zacksenhaus, N. Zaffaroni, T. Zaglia, Z. Zakeri, V. Zecchini, J. Zeng, M. Zeng, Q. Zeng, A.S. Zervos, D.D. Zhang, F. Zhang, G. Zhang, G.C. Zhang, H. Zhang, H. Zhang, H. Zhang, H. Zhang, H. Zhang, J. Zhang, J. Zhang, J. Zhang, J. Zhang, J.P. Zhang, L. Zhang, L. Zhang, L. Zhang, L. Zhang, L. Zhang, M.Y. Zhang, X. Zhang, X.D. Zhang, Y. Zhang, Y. Zhang, Y. Zhang, Y. Zhang, Y. Zhang, Y. Zhang, M. Zhao, W.L. Zhao, W.L. Zhao, W.L. Zhao, X. Zhao, Y.G. Zhao, Y. Zhao, Y. Zhao, Y.X. Zhao, Z. Zhao, Z.J. Zhao, D. Zheng, X.L. Zheng, X. Zheng, B. Zhivotovsky, B. Zhivotovsky, Q. Zhong, Q. Zhong, G.Z. Zhou, G. Zhou, H. Zhou, S.F. Zhou, X.J. Zhou, X.J. Zhou, X.J. Zhou, H. Zhu, H. Zhu, W.G. Zhu, W. Zhu, X.F. Zhu, Y. Zhu, S.M. Zhuang, X. Zhuang, E. Ziparo, C.E. Zois, T. Zoladek, W.X. Zong, A. Zorzano, A. Zorzano, A. Zorzano, S.M. Zughaier, Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition), *Autophagy*. 12 (2016) 1–222. doi:10.1080/15548627.2015.1100356.
- [22] S. Ghavami, S. Shojaei, B. Yeganeh, S.R. Ande, J.R. Jangamreddy, M. Mehrpour, J. Christoffersson, W. Chaabane, A.R. Moghadam, H.H. Kashani, M. Hashemi, A.A. Owji, M.J. Łos, Autophagy and apoptosis dysfunction in neurodegenerative disorders, *Prog. Neurobiol.* 112 (2014) 24–49. doi:10.1016/j.pneurobio.2013.10.004.
- [23] S.C. Correia, R. Resende, P.I. Moreira, C.M. Pereira, Alzheimer's Disease-Related Misfolded Proteins and Dysfunctional Organelles on Autophagy Menu, *DNA Cell Biol.* 34 (2015) 261–273. doi:10.1089/dna.2014.2757.
- [24] A. Peric, W. Annaert, Early etiology of Alzheimer's disease: tipping the balance toward autophagy or endosomal dysfunction?, *Acta Neuropathol.* 129 (2015) 363–381. doi:10.1007/s00401-014-1379-7.
- [25] P. Melnyk, S. Burlet, N. Le Fur, A. Delacourte, Heterocycle compounds and uses thereof for the treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs, US 8,680,095 B2, 2014. doi:10.1126/science.Liquids.
- [26] P. Melnyk, N. Sergeant, L. Buée, A. Delacourte, Use of 1,4-bis(3-aminoalkyl)piperazine derivatives in the treatment of neurodegenerative diseases., WO 2006 051489, 2006.

- [27] P. Melnyk, P. Carato, S. Burlet, T.H. Nguyen, P. Verwaerde, N. Sergeant, C. Estrella, Beta and gamma-carbolines derivatives for the treatment of neurodegenerative diseases., WO 2014 207240, 2014.
- [28] M. Barrier, L. Buée, S. Burlet, A. Delacourte, C. Estrella, P. Melnyk, N. Sergeant, P. Verwaerde, Sulfate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same., WO 2014 102339, 2014.
- [29] S.Y. Yang, Pharmacophore modeling and applications in drug discovery: Challenges and recent advances, *Drug Discov. Today*. 15 (2010) 444–450. doi:10.1016/j.drudis.2010.03.013.
- [30] M. Gay, P. Carato, M. Coevoet, N. Renault, P.E. Larchanché, A. Barczyk, S. Yous, L. Buée, N. Sergeant, P. Melnyk, New phenylaniline derivatives as modulators of amyloid protein precursor metabolism, *Bioorganic Med. Chem.* 26 (2018) 2151–2164. doi:10.1016/j.bmc.2018.03.016.
- [31] P. Carato, P. Depreux, D. Lesieur, M. Millan, A. Newman-Tancredi, M.C. Rettori, D.H. Caignard, Synthesis and binding studies on a new series of arylpiperazino benzoxazol-2-one and benzoxazin-3-one derivatives as selective D4 ligands, *Drug Des. Disc.* 17 (2000) 173–181.
- [32] S. Bhattacharyya, Reductive Alkylations of Dimethylamine Using Titanium(IV) Isopropoxide and Sodium Borohydride: An Efficient, Safe, and Convenient Method for the Synthesis of N,N-Dimethylated Tertiary Amines, *J. Org. Chem.* 60 (1995) 4928–4929. doi:10.1021/jo00120a044.
- [33] G. Sbardella, A. Mai, M. Artico, R. Loddo, M.G. Setzu, P. La Colla, Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480, *Bioorganic Med. Chem. Lett.* 14 (2004) 1537–1541. doi:10.1016/j.bmcl.2004.01.010.
- [34] J. Ermolieff, J.A. Loy, G. Koelsch, J. Tang, Proteolytic activation of recombinant pro-memapsin 2 (pro- β -secretase) studied with new fluorogenic substrates, *Biochemistry*. 39 (2000) 12450–12456. doi:10.1021/bi001494f.
- [35] A. Yamamoto, Y. Tagawa, T. Yoshimori, Y. Moriyama, R. Masaki, Y. Tashiro, Bafilomycin A1 Prevents Maturation of Autophagic Vacuoles by Inhibiting Fusion between Autophagosomes and Lysosomes in Rat Hepatoma Cell Line, H-4-II-E Cells, *Cell Struct. Funct.* 23 (1998) 33–42. doi:10.1247/csf.23.33.
- [36] J. Taminiau, G. Thijs, H. De Winter, Pharao: Pharmacophore alignment and

optimization, *J. Mol. Graph. Model.* 27 (2008) 161–169.

doi:10.1016/j.jmglm.2008.04.003.

- [37] N. Sergeant, J.P. David, D. Champain, A. Ghestem, A. Wattez, A. Delacourte, Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer's disease, *J. Neurochem.* 81 (2002) 663–672. doi:10.1046/j.1471-4159.2002.00901.x.
- [38] M. Domise, S. Didier, C. Marinangeli, H. Zhao, P. Chandakkar, L. Buée, B. Viollet, P. Davies, P. Marambaud, V. Vingtdeux, AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo, *Sci. Rep.* 6 (2016) 1–12. doi:10.1038/srep26758.

Figure 1. Amyloid protein precursor (APP) processing.

A

A1

B1

B

Figure 2. Design of biaryl series based on series A and B. A. Structure of compound A1 and B1, representative compounds of series A and B, respectively. B. Ligand-based approach leading to biaryl series.

A

B

Figure 3. Effect of target compounds on α CTF (A) and AICD (B) stabilities. The effect of reference and tested compounds at 1, 3 and 10 μ M are expressed as the intensity of corresponding Western Blot bands of at least three independent experiments.

Figure 4. Comparison of compounds 30 and 31 effect on APP metabolism in SY5Y-APP^{695WT} cells. SY5Y-APP_{wt} cells were treated for 24h with increasing concentrations of compound 30 (Cpd 30) or compound 31 (Cpd 31) as indicated. Cell lysates were immunolabeled with the following antibodies: APP-Cter-C17 and β-actin as loading control (panel A and B). Densitometric analysis and quantification of immature and mature APP levels (panel C, D, E and F), APP α-carboxy-terminal fragments and AICD (panel G, H, I and J). Conditioned medium was analysed by ELISA to measure secreted Aβ₁₋₄₀ and Aβ₁₋₄₂ peptides (panel K, L, M and N) and by electro-chemiluminescence immunoassay to measure secreted sAPPα and sAPPβ (panel O, P, Q and R). Histograms indicate the mean ± SD. a. u., arbitrary units, n=6 *p<0.05, **p<0.01, ***p<0.005, ****p<0.001 Mann-Whitney.

Figure 5. Effect of compound 30 on the autophagic flux in SY5Y-APP_{wt} cells. SY5Y-APP_{wt} cells were treated for 24h with increasing concentrations of compound 30 (Cpd 30) or compound 31 (Cpd 31) as indicated and co-treated with Bafilomycin A1 (Baf_{A1}) at 100nM or not. Cell lysates were immunolabeled with the following antibodies: p62, LC3-B and β-actin, used as loading control (panel A and F). Densitometric analysis and quantification of p62/β-actin (panel B and C) and LC3-II/LC3-I ratio (panel D, E, G and H) expressed in % to control. Histograms indicate the mean ± SD. a. u., arbitrary units. n=6 *p<0.05, **p<0.01, ***p<0.005, ****p<0.001 Mann-Whitney. Immunofluorescence staining of p62 (red, panel I) and LC3-B (red, panel J) in SY5Y-APP_{wt} cells after 24h of compound 30 treatment at 5μM versus untreated cells. Scale bars = 25μm.

24-36

Cpd	X	n	m	CHO substituent
24	N	3	2	<i>p</i> -CH ₂ -piperidine
25	N	3	2	<i>p</i> -CH ₂ -N(Me) ₂
26	N	3	2	<i>m</i> -CH ₂ -piperidine
27	N	3	2	<i>o</i> -CH ₂ -piperidine
28	N	3	2	<i>o</i> -CH ₂ -morpholine
29	N	3	2	<i>o</i> -CH ₂ -N-methylpiperazine
30	N	3	2	<i>o</i> -CH ₂ -N(Me) ₂
31	CH	3	2	<i>o</i> -CH ₂ -N(Me) ₂
32	N	3	3	<i>o</i> -CH ₂ -N(Me) ₂
33	N	2	2	<i>o</i> -CH ₂ -N(Me) ₂
34	N	2	3	<i>o</i> -CH ₂ -N(Me) ₂
35	N	2	4	<i>o</i> -CH ₂ -N(Me) ₂
36	N	4	2	<i>o</i> -CH ₂ -N(Me) ₂

15-23

Cpd	X	n	m	CHO substituent
15	N	3	2	<i>o</i> -CHO
16	N	3	2	<i>m</i> -CHO
17	N	3	2	<i>p</i> -CHO
18	N	2	2	<i>o</i> -CHO
19	N	2	3	<i>o</i> -CHO
20	N	2	4	<i>o</i> -CHO
21	N	3	3	<i>o</i> -CHO
22	N	4	2	<i>o</i> -CHO
23	CH	3	2	<i>o</i> -CHO

8-14

Cpd	X	n	m
8	N	2	2
9	N	2	3
10	N	2	4
11	N	3	2
12	N	3	3
13	N	4	2
14	CH	3	2

37

Cpd	X	n	m
37	N	3	2

Scheme 2^a. Synthesis of compounds **39**, **41** and **44**.

^a *Reagents and conditions:* (a) 1-(2-Chloroethyl)piperidine hydrochloride K_2CO_3 , ACN, 80 °C, 12 h, 41-91%; (b) **38**, 2-Formylphenylboronic acid, K_2CO_3 , $\text{P}(o\text{-tol})_3$, Pd_2dba_3 , toluene, EtOH, reflux, 18 or 96 h, 40-68%; (c) Procedure A: Dimethylamine 2M in THF, $\text{NaBH}(\text{OAc})_3$, AcOH, DCE, rt, 18 h, 26%. Procedure B: *i*) Dimethylamine hydrochloride, Et_3N , Titanium isopropoxide, EtOH, rt, 12 h, *ii*) NaBH_4 , rt, 2 h, 40%; (d) 3-Chloropropylpiperidine hydrochloride, NaI, K_2CO_3 , DMF, 100 °C, 24 h, 23%.

Scheme 3^a. Synthesis of compound **51**.

^a *Reagents and conditions:* (a) 70% HNO₃, rt, 4 h, 87%; (b) 3-Chloropropylpiperidine hydrochloride, K₂CO₃, ACN, reflux, 5 h, 98%; (c) 2.5N NaOH, dioxane, rt, 48 h, 50-95%; (d) 1-(2-Chloroethyl)piperidine, K₂CO₃, ACN, 5 h, 60 °C, 72%; (e) HCOONH₄, EtOH, reflux, 1 h 30, 39% (f) 2,5-Dimethoxy-3-tetrahydrofurancarboxaldehyde, AcOH, 90 °C, 2 h, 43%; (g) Dimethylamine 2M in THF, NaBH(OAc)₃, AcOH, DCE, rt, 18 h, 31%.

Table 1. Effects of compounds 24-37, 39, 41, 44 and 51 on A β ₁₋₄₀ and A β ₁₋₄₂ secretion

24-37					39: R = H 41: R = -CH ₂ -N(Me) ₂		44	51
Cpd	X	n	m		A β ₁₋₄₀ IC ₅₀ (μ M) ^a	A β ₁₋₄₂ IC ₅₀ (μ M) ^a	α CTF vs CQ (3 μ M) ^{b,c}	AICD vs CQ (3 μ M) ^{b,d}
CQ					7.0	12.7	1	1
A1					1.7 $\pm$ 0.2	2.1 $\pm$ 0.5	1.3	1.8
B1					5.1 $\pm$ 0.1	11.2 $\pm$ 4.2	2.1	2.5
24	N	3	2	<i>p</i> -CH ₂ -piperidine	2.1 $\pm$ 0.6	3.3 $\pm$ 2.1	2.6	2.5
25	N	3	2	<i>p</i> -CH ₂ -N(Me) ₂	1.5 $\pm$ 0.1	1.7 $\pm$ 0.4	2.1	2.5
26	N	3	2	<i>m</i> -CH ₂ -piperidine	4.3 $\pm$ 0.7	4.8 $\pm$ 0.6	3.3	2.6
27	N	3	2	<i>o</i> -CH ₂ -piperidine	2.6 $\pm$ 0.1	4.1 $\pm$ 1.3	4.3	2.7
28	N	3	2	<i>o</i> -CH ₂ -morpholine	2.8 $\pm$ 1.2	4.2 $\pm$ 1.5	3.1	1.7
29	N	3	2	<i>o</i> -CH ₂ -N-methylpiperazine	2.6 $\pm$ 0.2	2.7 $\pm$ 0.8	5.1	3.7
30	N	3	2	<i>o</i> -CH ₂ -N(Me) ₂	2.8 $\pm$ 1.2	3.4 $\pm$ 1.9	6.4	3.6
31	CH	3	2	<i>o</i> -CH ₂ -N(Me) ₂	2.1 $\pm$ 0.3	2.8 $\pm$ 0.1	0.1	0.1
32	N	3	3	<i>o</i> -CH ₂ -N(Me) ₂	2.1 $\pm$ 0.3	2.0 $\pm$ 0.1	4.5	5.1
33	N	2	2	<i>o</i> -CH ₂ -N(Me) ₂	1.4 $\pm$ 0.5	1.2 $\pm$ 0.6	5.0	4.8
34	N	2	3	<i>o</i> -CH ₂ -N(Me) ₂	2.0 $\pm$ 0.2	1.8 $\pm$ 0.7	4.5	3.4
35	N	2	4	<i>o</i> -CH ₂ -N(Me) ₂	1.6 $\pm$ 0.1	1.6 $\pm$ 0.3	4.4	4.8
36	N	4	2	<i>o</i> -CH ₂ -N(Me) ₂	1.7 $\pm$ 0.3	1.6 $\pm$ 0.8	4.2	3.0
37	N	3	2	/	5.2 $\pm$ 0.1	4.0 $\pm$ 0.4	2.4	2.1
39					9.1 $\pm$ 0.6	13.7 $\pm$ 3.3	0.1	0.2
41					1.5 $\pm$ 0.3	1.2 $\pm$ 0.3	0.6	0.7
44					3.9 $\pm$ 1.0	3.6 $\pm$ 0.1	0.9	0.8
51					5.0 $\pm$ 0.9	6.5 $\pm$ 2.0	3.6	2.0

^a Compound concentration inhibiting 50% of A β ₁₋₄₀ or A β ₁₋₄₂ peptide secretion in SY5Y cells.

IC₅₀ values are expressed as mean $\pm$ SD of at least two experiments performed in triplicate. ^b

Mean values calculated on the basis of at least three independent experiments with less than

10% deviation. ^c CTF α increase compared to chloroquine ([CTF]compound/[CTF]CQ) at 3 μ M.

^d AICD increase compared to chloroquine ([AICD]compound/[AICD]CQ) at 3 μ M